CH578464A5 - - Google Patents

Info

Publication number
CH578464A5
CH578464A5 CH812973A CH812973A CH578464A5 CH 578464 A5 CH578464 A5 CH 578464A5 CH 812973 A CH812973 A CH 812973A CH 812973 A CH812973 A CH 812973A CH 578464 A5 CH578464 A5 CH 578464A5
Authority
CH
Switzerland
Application number
CH812973A
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of CH578464A5 publication Critical patent/CH578464A5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A61F6/142—Wirelike structures, e.g. loops, rings, spirals
    • A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CH812973A 1972-06-05 1973-06-05 CH578464A5 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00259469A US3845770A (en) 1972-06-05 1972-06-05 Osmatic dispensing device for releasing beneficial agent

Publications (1)

Publication Number Publication Date
CH578464A5 true CH578464A5 (hr) 1976-08-13

Family

ID=22985088

Family Applications (1)

Application Number Title Priority Date Filing Date
CH812973A CH578464A5 (hr) 1972-06-05 1973-06-05

Country Status (12)

Country Link
US (1) US3845770A (hr)
JP (1) JPS596843B2 (hr)
AR (1) AR199301A1 (hr)
BR (1) BR7304196D0 (hr)
CH (1) CH578464A5 (hr)
ES (1) ES415568A1 (hr)
FR (1) FR2188568A5 (hr)
GB (1) GB1415210A (hr)
IE (1) IE39952B1 (hr)
IL (1) IL42418A (hr)
NL (1) NL163721C (hr)
ZA (1) ZA733734B (hr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100424A2 (en) * 1982-06-30 1984-02-15 Merck & Co. Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance

Families Citing this family (2062)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3996933A (en) * 1972-10-02 1976-12-14 Morton Gutnick Intrauterine contraceptive devices and processes
US4325388A (en) * 1973-02-05 1982-04-20 Louis Bucalo Apparatus for collecting and processing body fluids
US3971376A (en) * 1973-02-26 1976-07-27 Ceskoslovenska Akademie Ved Method and apparatus for introducing fluids into the body
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
GB1465684A (en) * 1973-07-27 1977-02-23 Emmett L Contraceptive device
US4111196A (en) * 1973-07-27 1978-09-05 Lionel C. R. Emmett Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
US4018220A (en) * 1974-07-19 1977-04-19 Lionel C. R. Emmett Method of insertion for intrauterine device of C or omega form with tubular inserter
US4172446A (en) * 1974-12-20 1979-10-30 Louis Bucalo Apparatus for collecting body fluids
US4093708A (en) * 1974-12-23 1978-06-06 Alza Corporation Osmotic releasing device having a plurality of release rate patterns
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
ZA761193B (en) * 1975-03-19 1977-02-23 Procter & Gamble Controlled release articles
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4073833A (en) * 1975-12-08 1978-02-14 The Procter & Gamble Company Encapsulation process
US4031202A (en) * 1975-12-08 1977-06-21 The Procter & Gamble Company Controlled release contraceptive article
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
SE448203B (sv) * 1980-09-10 1987-02-02 Johan Alfred Olof Johansson formkropp framstelld av agar och/eller agaros och/eller ett derivat derav innehallande farmakologiskt verksamt emne
US4439195A (en) * 1980-10-14 1984-03-27 Alza Corporation Theophylline therapy
US4455145A (en) * 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4552555A (en) * 1981-07-31 1985-11-12 Alza Corporation System for intravenous delivery of a beneficial agent
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
GR76223B (hr) * 1981-07-31 1984-08-04 Alza Corp
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4416659A (en) * 1981-11-09 1983-11-22 Eli Lilly And Company Sustained release capsule for ruminants
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4539004A (en) * 1982-09-22 1985-09-03 Alza Corporation Self-driven pump assembly and method of operation
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4552561A (en) * 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4859667A (en) * 1983-01-21 1989-08-22 Merck Frosst Canada, Inc. Pharmaceutical compositions of phenothiazone derivatives and analogs
US4667032A (en) * 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4610686A (en) * 1983-11-02 1986-09-09 Alza Corporation Controlled delivery of haloperidol by an osmotic delivery system
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4729793A (en) * 1985-08-09 1988-03-08 Alza Corporation Composition for manufacturing wall of dispensing device
US4844984A (en) * 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
US4612186A (en) * 1984-03-19 1986-09-16 Alza Corporation Method for establishing blood levels of biocide in animals
US4624945A (en) * 1984-03-19 1986-11-25 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US5000957A (en) * 1984-03-19 1991-03-19 Alza Corporation Dispenser comprising hydrophilic osmopolymer
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
EP0203186B1 (en) * 1984-12-03 1992-03-04 BAXTER INTERNATIONAL INC. (a Delaware corporation) Drug delivery apparatus preventing local and systemic toxicity
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
JPS61153350U (hr) * 1985-03-13 1986-09-22
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
US4717718A (en) * 1985-08-09 1988-01-05 Alza Corporation Device for the controlled delivery of a beneficial agent
US4717568A (en) * 1985-08-09 1988-01-05 Alza Corporation Laminar arrangement for increasing delivery of beneficial agent from dispenser
US4963141A (en) * 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
US4643731A (en) * 1985-08-16 1987-02-17 Alza Corporation Means for providing instant agent from agent dispensing system
US4966767A (en) * 1985-08-16 1990-10-30 Alza Corporation Ruminant dispensing device comprising agent displacement member
US5098425A (en) * 1985-08-16 1992-03-24 Alza Corporation Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member
US4883667A (en) * 1985-08-16 1989-11-28 Alza Corporation Process for forming dispensing device
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4955881A (en) * 1985-08-16 1990-09-11 Alza Corporation Ruminant dispensing device
US4871544A (en) * 1985-08-16 1989-10-03 Alza Corporation Ruminant dispensing device
US4704118A (en) * 1985-08-16 1987-11-03 Alza Corporation Ruminant dispensing device with thermo-activated memory
US4756314A (en) * 1985-10-28 1988-07-12 Alza Corporation Sweat collection patch
US4680266A (en) * 1985-11-21 1987-07-14 Contraves Ag Cell culture chamber with means for automatic replenishment of nutrient
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US4838862A (en) 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
EP0277092B1 (de) * 1987-01-14 1992-01-29 Ciba-Geigy Ag Therapeutisches System für schwerlösliche Wirkstoffe
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US5023076A (en) * 1987-02-27 1991-06-11 Alza Corporation Lamina comprising carboxyvinyl polymer
US4915952A (en) * 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4886668A (en) * 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US4950486A (en) * 1987-10-02 1990-08-21 Alza Corporation Dosage form for treating cardiovascular diseases
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5030203A (en) * 1987-11-16 1991-07-09 Baxter International Inc. Ampule for controlled administration of beneficial agent
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5030456A (en) * 1988-11-07 1991-07-09 Alza Corporation Dosage form for treating cardiovascular diseases
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5728088A (en) * 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US4969872A (en) * 1989-03-08 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US20020197309A1 (en) * 1989-09-05 2002-12-26 Kuczynski Anthony L. Method for lowering blood glucose
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5071607A (en) * 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
US5024663A (en) * 1990-02-21 1991-06-18 Alza Corporation Self-contained suction pump
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5147654A (en) * 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
DE69107461T2 (de) * 1990-08-07 1995-06-22 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5246709A (en) * 1990-09-10 1993-09-21 Alza Corporation Antiemetic therapy
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
ES2053339T3 (es) * 1990-09-28 1994-07-16 Pfizer Dispositivo dispensador conteniendo un medio hidrofobo.
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5861166A (en) * 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5801141A (en) * 1991-06-24 1998-09-01 American Cyanamid Company Implant compositions containing a biologically active protein, peptide or polypeptide
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5254349A (en) * 1991-12-06 1993-10-19 Alza Corporation Process for lessening irritation caused by drug
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
CA2151742C (en) * 1993-02-22 1999-05-25 Alfred A. Amkraut Compositions for oral delivery of active agents
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5985328A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US5770076A (en) * 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5985164A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Method for forming a filter
US5798042A (en) * 1994-03-07 1998-08-25 Regents Of The University Of California Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US6491945B1 (en) 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5595759A (en) * 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5651979A (en) * 1995-03-30 1997-07-29 Gel Sciences, Inc. Apparatus and method for delivering a biologically active compound into a biological environment
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5690952A (en) * 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5798119A (en) * 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
PT914097E (pt) * 1996-03-12 2002-06-28 Alza Corp Composicao e forma de dosagem compreendendo antagonista de opioide
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
DE69720735T9 (de) * 1996-08-12 2005-08-25 Celgene Corp. Immunotherapeutische mittel und ihre anwendung in der reduzierung der cytokininwerte
ATE205381T1 (de) * 1996-10-18 2001-09-15 Alza Corp Austragevorrichtung für aktive wirkstoffe
AU729905B2 (en) * 1996-10-18 2001-02-15 Alza Corporation Multiple flow path device for oral delivery of discrete units
US6024721A (en) 1996-10-18 2000-02-15 Alza Corporation Mixing system for an active agent delivery device
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
ES2255103T3 (es) * 1996-10-25 2006-06-16 Shire Laboratories Inc. Sistema osmotico de administracion de dosis en forma soluble.
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
JP4380800B2 (ja) 1997-03-07 2009-12-09 バーナリス リサーチ リミテッド マラリアの処置のための（＋）メフロキンの使用
DK1304105T3 (da) * 1997-03-31 2006-11-20 Alza Corp Implanterbart diffusionsafleveringssystem
IL159636A0 (en) * 1997-03-31 2004-06-01 Alza Corp Method for preparing a sustained release delivery system
ATE221762T1 (de) * 1997-05-16 2002-08-15 Alza Corp Durchflussreglerkonfigurationen für ein wirkstoff abgebendes gerät
US5994148A (en) * 1997-06-23 1999-11-30 The Regents Of University Of California Method of predicting and enhancing success of IVF/ET pregnancy
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US6245042B1 (en) 1997-08-27 2001-06-12 Science Incorporated Fluid delivery device with temperature controlled energy source
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
PT1014951E (pt) * 1997-09-09 2005-03-31 Alza Corp Composicao de revestimento farmaceutica e metodo para a sua utilizacao
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
SI1017392T1 (en) 1997-09-25 2002-12-31 Bayer Aktiengesellschaft Medicament formulation with a controlled release of an active agent
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US6607751B1 (en) 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
WO1999026627A1 (en) 1997-11-26 1999-06-03 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU1534699A (en) 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
PT1041975E (pt) 1997-12-22 2003-01-31 Alza Corp Membranas de controlo de taxa para dispositivos de fornecimento controlado de drogas
AU773642C (en) 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ATE260640T1 (de) 1997-12-29 2004-03-15 Alza Corp Osmotisches verabreichungssystem mit stöpselrückhaltemechanismus
DE69834213T2 (de) 1997-12-31 2007-01-25 Alza Corp., Mountain View Osmotisches Abgabesystem für ein nützliches Mittel
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
AU2349999A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
AR014809A1 (es) 1998-04-03 2001-03-28 Advanced Medicine Inc Compuestos multiligazon, composicion farmaceutica, metodo para prepara dichos compuestos y uso de dichos compuestos para preparar medicamentos
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
TR200103760T2 (tr) 1998-06-15 2002-06-21 Sepracor Inc. Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
CA2333666A1 (en) 1998-06-15 1999-12-23 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
US6369039B1 (en) * 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US7890176B2 (en) * 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
CN1205922C (zh) 1998-07-24 2005-06-15 柳署弘 制备含有胆汁酸的澄清水溶液剂型
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
EP1112060B1 (en) * 1998-09-09 2005-12-07 ALZA Corporation Dosage form comprising liquid formulation
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
HUP0104993A3 (en) 1998-11-02 2003-02-28 Alza Corp Mountain View Method and device for controlled delivery of active agents
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE60040979D1 (de) 1999-05-07 2009-01-15 Wockhardt Ltd (s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DK1225881T3 (da) 1999-09-03 2006-06-12 Apbi Holdings Llc Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6638263B1 (en) 1999-10-12 2003-10-28 Durect Corporation Regulation of drug delivery through flow diversion
US6114346A (en) 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
BRPI0015284B8 (pt) 1999-10-29 2021-05-25 Euro Celtique S/A formulações de hidrocodona de liberação controlada
KR100738276B1 (ko) * 1999-12-09 2007-07-12 알자 코포레이션 항바이러스성 약제
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6432446B2 (en) 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
JP2004500378A (ja) * 2000-02-04 2004-01-08 ヨー、セオ、ホン 胆汁酸を含有する清浄水溶液製型の製造
DE60135441D1 (de) 2000-02-08 2008-10-02 Euro Celtique Sa Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten
JP2003522144A (ja) 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
US6616652B1 (en) 2000-02-15 2003-09-09 Microsolutions, Inc. Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
BR0108452A (pt) 2000-02-18 2003-04-01 Cv Therapeutics Inc Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
AU2001238665A1 (en) 2000-02-23 2001-09-03 Cv Therapeutics, Inc. Method of identifying partial agonists of the a2a receptor
US6582441B1 (en) 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US6569152B2 (en) * 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
MXPA02009665A (es) * 2000-03-31 2005-09-08 Celgene Corp Inhibicion de actividad de ciclooxigenasa-2.
CA2407154A1 (en) 2000-04-27 2001-11-01 Verion, Inc Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
AU2001296770A1 (en) * 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
EP1723948A1 (en) 2000-11-03 2006-11-22 Andrx Labs, LLC Controlled release compositions of biguanide with less side effects and treatment regimen thereof
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20070208087A1 (en) * 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
CA2429411A1 (en) * 2000-11-17 2002-05-23 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
US20030195706A1 (en) * 2000-11-20 2003-10-16 Michael Korenberg Method for classifying genetic data
JP4248236B2 (ja) * 2000-11-29 2009-04-02 デュレクト コーポレイション 薬物送達装置からの送達を制御するための装置および方法
ES2250504T3 (es) 2000-11-29 2006-04-16 Allergan Inc. Prevencion del rechazo de injerto en el ojo.
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
AU2002221412B2 (en) 2000-12-05 2006-04-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
EP1341773A2 (en) 2000-12-07 2003-09-10 Cv Therapeutics, Inc. Substituted 1,3,5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
US20060064140A1 (en) * 2001-01-30 2006-03-23 Whitehurst Todd K Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
US20050143789A1 (en) * 2001-01-30 2005-06-30 Whitehurst Todd K. Methods and systems for stimulating a peripheral nerve to treat chronic pain
US7493172B2 (en) * 2001-01-30 2009-02-17 Boston Scientific Neuromodulation Corp. Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
IN190699B (hr) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
ES2290281T5 (es) * 2001-02-12 2017-09-11 Wyeth Llc Sal de succinato de O-desmetil-venlafaxina
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
KR20040011480A (ko) 2001-03-22 2004-02-05 덴드레온 샌 디에고 엘엘씨 세린 프로테아제 ｃｖｓｐ14를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
EP1379637A4 (en) 2001-03-27 2005-04-06 Dendreon Corp TRANSMEMBRANE SERINE PROTEASE 9 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED, AND METHODS FORMING THEREOF
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6632217B2 (en) * 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US6964966B2 (en) * 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) * 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
EP1539942A4 (en) 2001-05-14 2005-10-19 Dendreon Corp A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF
EP1404324B2 (en) * 2001-06-11 2011-04-06 XenoPort, Inc. Prodrugs of gaba analogs, compositions and uses thereof
JP2005501013A (ja) * 2001-06-11 2005-01-13 ゼノポート，インコーポレイテッド Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
US20040247696A1 (en) * 2001-07-05 2004-12-09 Antelman Marvin S. Methods of using electron active compounds for managing conditions afflicting mammals
WO2003004030A1 (en) 2001-07-06 2003-01-16 Endo Pharmaceuticals, Inc. Oxymorphone controlled release formulations
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
ES2292775T3 (es) 2001-07-06 2008-03-16 Penwest Pharmaceuticals Co. Formulaciones de liberacion prolongada de oximorfona.
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
SI1414451T1 (sl) 2001-08-06 2009-10-31 Euro Celtique Sa Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
EP1283025A1 (de) * 2001-08-10 2003-02-12 Stöckert Instrumente GmbH Ballonokklusionsvorrichtung
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
BR0212951A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
IL161867A0 (en) 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US7157493B2 (en) * 2001-11-28 2007-01-02 Nashai Biotech, Llc Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
WO2003049673A2 (en) 2001-12-05 2003-06-19 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
AU2002357935A1 (en) * 2001-12-18 2003-06-30 Alza Corporation Dosage form for providing time-varying patterns of drug delivery
US20030198619A1 (en) * 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20030232078A1 (en) * 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
ES2309294T3 (es) 2002-02-01 2008-12-16 Pfizer Products Inc. Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20040260076A1 (en) * 2002-10-11 2004-12-23 Castillo Gerardo M. Isolation, purification and synthesis of procyanidin B2 and uses thereof
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
AU2003223237C1 (en) 2002-02-19 2009-03-26 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors
AU2002316231A1 (en) 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
KR101173497B1 (ko) * 2002-03-11 2012-08-14 알콘, 인코퍼레이티드 이식 가능한 약물 전달 시스템
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
JP2005521706A (ja) * 2002-03-29 2005-07-21 アルザ・コーポレーシヨン 体積効果的放出制御製剤
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
ES2733044T1 (es) * 2002-04-05 2019-11-27 Mundipharma Pharmaceuticals S L Composición farmacéutica que contiene oxicodona y naloxona
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20060116663A1 (en) * 2002-05-01 2006-06-01 Joshi Ashok V Electro-osmotic fluid delivery device and method
US7470267B2 (en) * 2002-05-01 2008-12-30 Microlin, Llc Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
US7896867B2 (en) * 2002-05-01 2011-03-01 Microlin, Llc Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
US7458965B2 (en) * 2002-05-01 2008-12-02 Microlin, Llc Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
CN1697655B (zh) 2002-05-17 2013-09-18 细胞基因公司 使用免疫调节性化合物用于治疗和控制癌症和其它疾病的方法及组合物
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2003099338A2 (en) * 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
NZ536908A (en) * 2002-05-17 2008-09-26 Celgene Corp Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient
EP1505977B1 (en) 2002-05-21 2014-09-10 Gilead Sciences, Inc. Administration of a partial fatty acid oxidation inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7151961B1 (en) * 2002-05-24 2006-12-19 Advanced Bionics Corporation Treatment of movement disorders by brain stimulation
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
SI2527315T1 (sl) 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CN1671358A (zh) * 2002-05-31 2005-09-21 阿尔扎公司 用于渗透传递可变剂量的羟考酮的剂型和组合物
AU2003243354A1 (en) * 2002-05-31 2003-12-19 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US6900203B2 (en) 2002-06-19 2005-05-31 Polium Technologies, Inc. Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
JP2005533084A (ja) * 2002-06-28 2005-11-04 アルザ・コーポレーシヨン 液体の有効成分の製剤を含んでなりかつ膨張可能な浸透圧組成物によりその放出を制御する経口の投薬形態
TWI326214B (en) 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
CN1688303A (zh) 2002-07-23 2005-10-26 密歇根大学董事会 用于抗血管发生疗法的四硫代钼酸四丙铵及相关化合物
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7683037B2 (en) * 2002-07-29 2010-03-23 Gilead Palo Alto, Inc. Myocardial perfusion imaging method
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US7254449B2 (en) * 2002-07-31 2007-08-07 Advanced Bionics Corp Systems and methods for providing power to one or more implantable devices
ES2358896T3 (es) 2002-08-15 2011-05-16 Euro-Celtique S.A. Composiciones farmacéuticas que comprenden un analgésico opioide.
US20040132806A1 (en) 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
US20060009739A1 (en) * 2002-09-06 2006-01-12 Durect Corporation Implantable flow regulator with failsafe mode and reserve drug supply
EP1545551A4 (en) 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
EP2422775A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
KR20120034211A (ko) 2002-09-20 2012-04-10 안드렉스 랩스 엘엘씨 약제학적 정제
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004029059A1 (en) 2002-09-25 2004-04-08 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
WO2004029025A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of autoimmune disorders using clofarabine
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
CA2500091A1 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
CA2501625A1 (en) * 2002-10-07 2004-04-22 Radiorx, Inc. X-nitro compounds, pharmaceutical compositions thereof and uses therof
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1551385A4 (en) * 2002-10-15 2008-10-22 Celgene Corp SELECTIVE CYTOKINE INHIBITOR DRUGS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
UY28056A1 (es) * 2002-10-31 2003-12-31 Alza Corp Formas de dosificacion que proporcionan la liberacion ascendente de una formulacion liquida.
EP1556000A1 (en) * 2002-10-31 2005-07-27 Alza Corporation Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs
EP1567169A4 (en) * 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
MXPA05004780A (es) 2002-11-06 2005-10-05 Celgene Corp Metodos y composiciones que usan farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de canceres y otros padecimientos.
NZ540384A (en) * 2002-11-06 2008-06-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
JP2006510617A (ja) * 2002-11-18 2006-03-30 セルジーン・コーポレーション （＋）−３−（３，４−ジメトキシ−フェニル）−３−（１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−プロピオンアミドの使用方法およびそれを含む組成物
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EA200500871A1 (ru) * 2002-11-25 2006-04-28 Атеньюон, Ллк Пептиды, ингибирующие ангиогенез, миграцию клеток, инвазию клеток и пролиферацию клеток, композиции и их применение
AU2003293423A1 (en) 2002-12-06 2004-06-30 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20040111071A1 (en) * 2002-12-09 2004-06-10 Jeffrey Lewis Powers Portable device for dispensing hand treatments
US8286834B2 (en) * 2002-12-09 2012-10-16 Jeffrey Lewis Powers Skin treatment dispenser and method of manufacture
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
SI2218448T1 (sl) 2002-12-13 2016-01-29 Durect Corporation Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo
WO2004058147A2 (en) 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
RU2356549C2 (ru) * 2002-12-17 2009-05-27 Эббетт ГмбХ унд Ко.КГ Композиция, включающая фенофибриновую кислоту, ее физиологически приемлемую соль или производное
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006522016A (ja) * 2003-01-14 2006-09-28 アルザ・コーポレーシヨン 改変された粘度の層を用いる方法および投薬形態物
JP2006515891A (ja) 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
JP2006517593A (ja) * 2003-02-11 2006-07-27 アルザ・コーポレーシヨン 投薬形態物の層形状修飾方法およびそのような修飾を受けさせた投薬形態物
AR045414A1 (es) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
EP1608339B8 (en) 2003-02-28 2012-04-25 McNeill-PPC, Inc. Pharmaceutical co-crystal of celecoxib-nicotinamide
DK2163643T3 (en) 2003-03-05 2015-03-23 Halozyme Inc Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1608357A4 (en) * 2003-03-31 2008-03-26 Xenoport Inc TREATMENT OR PREVENTION OF HITZEWALLUNGEN USING PRODRUGS OF GABA ANALOGUE
SI3549936T1 (sl) 2003-04-11 2021-09-30 Ptc Therapeutics, Inc. Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
US20040214893A1 (en) * 2003-04-11 2004-10-28 Matthew Peterson Gabapentin compositions
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20070083240A1 (en) * 2003-05-08 2007-04-12 Peterson David K L Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
JP2007525188A (ja) 2003-05-16 2007-09-06 インターミューン インコーポレイテッド 合成ケモカイン受容体リガンドおよびその使用方法
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
JP2007502865A (ja) * 2003-05-23 2007-02-15 ブリッジ ファーマ、インコーポレイテッド 平滑筋鎮痙剤
US7186863B2 (en) * 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
CA2527236A1 (en) * 2003-05-27 2004-12-23 Attenuon Llc Thiotungstate analogues and uses thereof
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
AR044688A1 (es) * 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
EP1643946A2 (en) * 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
DK1641775T3 (da) * 2003-07-03 2009-04-20 Euro Celtique Sa 2-pyridinalkynderivater, der er anvendelige til behandling af smerter
WO2005004882A1 (en) * 2003-07-09 2005-01-20 Monash University Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
AU2004259024B2 (en) * 2003-07-23 2011-06-23 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
UA84710C2 (ru) * 2003-07-24 2008-11-25 Евро-Селтик С.А. Пиперидиновые производные, фармацевтическая композиция, которая их содержит, и способ лечения
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
MXPA06000940A (es) * 2003-07-24 2006-03-30 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento de dolor.
WO2005011630A2 (en) * 2003-07-31 2005-02-10 Alza Corporation Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
PL1648880T3 (pl) * 2003-08-01 2010-06-30 Euro Celtique Sa Środki lecznicze użyteczne do leczenia bólu
MXPA06001548A (es) * 2003-08-06 2006-09-04 Johnson & Johnson Suministro uniforme de topiramato durante un periodo prolongado con formulaciones de dispersion.
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
PT1660440E (pt) * 2003-08-20 2012-05-15 Xenoport Inc Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
WO2005020957A2 (en) * 2003-08-22 2005-03-10 Alza Corporation Stepwise delivery of topiramate over prolonged period of time
WO2005023181A2 (en) * 2003-08-22 2005-03-17 Vista Scientific Polymeric systems for controlled drug therapy
GB0320020D0 (en) * 2003-08-27 2003-10-01 Mw Encap Ltd Improved formulation for providing an enteric coating material
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
JP2007504261A (ja) * 2003-09-03 2007-03-01 エイジーアイ・セラピューティクス・リサーチ・リミテッド プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
DE60314920T2 (de) * 2003-09-04 2008-03-13 Wockhardt Ltd. Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
WO2005023204A2 (en) * 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US7700652B2 (en) 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
EP1677812A4 (en) * 2003-09-17 2010-03-24 Xenoport Inc TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
ATE412646T1 (de) * 2003-09-22 2008-11-15 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
EP1663229B1 (en) 2003-09-25 2010-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
AU2004275813A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Osmotic dosage forms for controlled delivery of alprazolam
WO2005030181A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
US20070259033A1 (en) 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
WO2005030166A1 (en) 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
CA2540045A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Dosage form for controlled release of an active agent formulation
DE602004006763T2 (de) * 2003-09-26 2008-02-07 Alza Corp., Mountain View Darreichungsform zur kontrollierten Freisetzung einer Formulierung mit aktivem Mittel und Verfahren zur Herstellung der Darreichungsform
BRPI0415288B8 (pt) * 2003-10-14 2021-05-25 Xenoport Inc composição farmacêutica compreendendo o ácido 1-{[(a- isobutanoiloxietoxi) carbonil] aminometil}- 1-ciclo- hexano acético cristalino
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
KR20060109922A (ko) * 2003-10-31 2006-10-23 알자 코포레이션 가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형
US20050118246A1 (en) * 2003-10-31 2005-06-02 Wong Patrick S. Dosage forms and layered deposition processes for fabricating dosage forms
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EA200600921A1 (ru) * 2003-11-06 2006-10-27 Селджин Корпорейшн Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
TW200528144A (en) * 2003-11-14 2005-09-01 Alza Corp Controlled release of topiramate in liquid dosage forms
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
EP2065383A1 (en) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
EP1689787A2 (en) 2003-11-28 2006-08-16 Eastman Chemical Company Cellulose interpolymers and method of oxidation
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005062829A2 (en) * 2003-12-19 2005-07-14 Advanced Bionics Corporation Skull-mounted electrical stimulation system and method for treating patients
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
AU2004308973A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
CA2551815A1 (en) * 2003-12-29 2005-07-21 Alza Corporation Novel drug compositions and dosage forms
AU2004312084A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
EP1702919B1 (en) * 2003-12-29 2012-05-30 Msd K.K. Novel 2-heteroaryl-substituted benzimidazole derivative
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
KR100867188B1 (ko) * 2003-12-30 2008-11-06 유로-셀띠끄 소시에떼 아노님 통증 치료에 유용한 피페라진
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
EP2194053B1 (en) 2004-01-07 2013-03-27 Armetheon, Inc. Methoxy piperidine derivatives for use inr the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
AU2005212005A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
ES2308451T3 (es) 2004-02-18 2008-12-01 Gpc Biotech Ag Satraplatino para el tratamiento de tumores resistentes o refractarios.
EP1729784A1 (en) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US7612071B2 (en) 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
NZ550026A (en) 2004-03-22 2009-10-30 Celgene Corp Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
WO2005092065A2 (en) * 2004-03-25 2005-10-06 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
TWI483944B (zh) 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
WO2005100346A1 (en) * 2004-04-08 2005-10-27 Wyeth Thioamide derivatives as progesterone receptor modulators
JP2007532642A (ja) * 2004-04-14 2007-11-15 セルジーン・コーポレーション 脊髄形成異常症候群の治療及び管理のための選択的サイトカイン阻害薬の使用法、及びそれを含む組成物
BRPI0418742A (pt) * 2004-04-14 2007-09-11 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
ZA200609228B (en) * 2004-04-23 2008-05-28 Celgene Corp Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
AU2005237520B2 (en) * 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8512738B2 (en) 2004-04-30 2013-08-20 Allergan, Inc. Biodegradable intravitreal tyrosine kinase implants
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
WO2005113596A2 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
CN1997633A (zh) * 2004-05-25 2007-07-11 麦它波莱克斯股份有限公司 作为ppar调节剂的取代的三唑及其制备方法
EP1755388B1 (en) 2004-05-28 2010-10-06 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
US20050267555A1 (en) * 2004-05-28 2005-12-01 Marnfeldt Goran N Engagement tool for implantable medical devices
ES2623362T3 (es) * 2004-05-28 2017-07-11 Human Biomolecular Research Institute Analgésicos metabólicamente estables y medicaciones para el dolor
WO2005120584A2 (en) * 2004-06-03 2005-12-22 The Trustees Of Columbia University In The City Of New York Radiolabeled arylsulfonyl compounds and uses thereof
WO2005121070A1 (en) * 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
ZA200610042B (en) * 2004-06-04 2008-06-25 Xenoport Inc Levodopa prodrugs, and compositions and uses thereof
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
WO2006025920A2 (en) * 2004-06-19 2006-03-09 Human Biomolecular Research Institute Modulators of central nervous system neurotransmitters
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
WO2006007351A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Squeeze controlled oral dosage form
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287212A1 (en) * 2004-06-28 2005-12-29 Liang-Chang Dong Oral delivery system comprising a drug/polymer complex
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20080027513A1 (en) * 2004-07-09 2008-01-31 Advanced Bionics Corporation Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
US7241807B2 (en) * 2004-07-12 2007-07-10 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
WO2006017352A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Amino acid derived prodrugs of propofol, compositions and uses thereof
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
MX2007001558A (es) * 2004-08-06 2008-03-13 Transform Pharmaceuticals Inc Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1786414A4 (en) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
SG164375A1 (en) * 2004-08-13 2010-09-29 Boehringer Ingelheim Int Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
EA201001083A1 (ru) * 2004-08-13 2011-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение
US8452407B2 (en) * 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
JP2008510000A (ja) * 2004-08-19 2008-04-03 アルザ・コーポレーシヨン 制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006025882A2 (en) 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
WO2006026555A2 (en) * 2004-08-30 2006-03-09 Seo Hong Yoo Neuroprotective effect of solubilized udca in focal ischemic model
JP5132310B2 (ja) * 2004-09-08 2013-01-30 スパイナル・モデュレーション・インコーポレイテッド 神経刺激の方法及びシステム
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
CN101083985A (zh) * 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
CN101039677A (zh) 2004-10-15 2007-09-19 Cv医药有限公司 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
JP2008516977A (ja) 2004-10-15 2008-05-22 セオ ホン ユー 薬剤学的化合物の毒性を減少させるための方法及び組成物
CA2583185A1 (en) * 2004-10-20 2006-04-27 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
US20090170790A1 (en) * 2004-10-25 2009-07-02 Biswajit Das Ketolide derivatives as antibacterial agents
BRPI0518062A (pt) * 2004-10-28 2008-10-28 Celgene Corp uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
ATE491456T1 (de) * 2004-11-01 2011-01-15 Seo Hong Yoo Verfahren und zusammensetzungen zur verringerung der neurodegeneration bei amyotrophischer lateralsklerose
MX2007005289A (es) 2004-11-02 2007-07-19 Banyu Pharma Co Ltd Derivados de bencimidazol ariloxi-sustituido.
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
CN101068538A (zh) * 2004-11-04 2007-11-07 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
US9358393B1 (en) 2004-11-09 2016-06-07 Andres M. Lozano Stimulation methods and systems for treating an auditory dysfunction
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP1828174A1 (en) * 2004-11-19 2007-09-05 Ranbaxy Laboratories Limited Azabicyclic muscarinic receptor antagonists
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US7483746B2 (en) * 2004-12-06 2009-01-27 Boston Scientific Neuromodulation Corp. Stimulation of the stomach in response to sensed parameters to treat obesity
WO2006065793A2 (en) 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. TREATMENT OF INTERSTITIAL CYSTITIS USING (6aR,10aR)-Δ8-TETRAHYDROCANNABINOL-11-OIC ACIDS
US20060128738A1 (en) * 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
ES2401285T3 (es) 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
SI2561872T1 (sl) 2004-12-17 2015-02-27 Anadys Pharmaceuticals, Inc. 3,5-disubstituirane in 3,5,7-trisubstituiran-3H-oksazolo in 3H-tiazolo(4,5-d)pirimidin-2-onske spojine in njihova predzdravila
US9327069B2 (en) 2004-12-21 2016-05-03 Boston Scientific Neuromodulation Corporation Methods and systems for treating a medical condition by promoting neural remodeling within the brain
US20060161217A1 (en) * 2004-12-21 2006-07-20 Jaax Kristen N Methods and systems for treating obesity
US9095713B2 (en) * 2004-12-21 2015-08-04 Allison M. Foster Methods and systems for treating autism by decreasing neural activity within the brain
US20070038264A1 (en) * 2004-12-21 2007-02-15 Jaax Kristen N Methods and systems for treating autism
US9352145B2 (en) * 2004-12-22 2016-05-31 Boston Scientific Neuromodulation Corporation Methods and systems for treating a psychotic disorder
US8515541B1 (en) 2004-12-22 2013-08-20 Boston Scientific Neuromodulation Corporation Methods and systems for treating post-stroke disorders
WO2006071995A1 (en) * 2004-12-23 2006-07-06 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
MX2007008290A (es) * 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
ES2567853T3 (es) 2005-01-25 2016-04-26 Synta Pharmaceuticals Corporation Compuestos contra la inflamación y utilizaciones relacionadas con el sistema inmunitario
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
US20060185665A1 (en) * 2005-02-22 2006-08-24 Bachinski Thomas J Sauna fireplace
US20060194724A1 (en) * 2005-02-25 2006-08-31 Whitehurst Todd K Methods and systems for nerve regeneration
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US7312217B2 (en) 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
US7920915B2 (en) * 2005-11-16 2011-04-05 Boston Scientific Neuromodulation Corporation Implantable stimulator
US7848803B1 (en) 2005-03-14 2010-12-07 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US8423155B1 (en) 2005-03-14 2013-04-16 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US7853321B2 (en) 2005-03-14 2010-12-14 Boston Scientific Neuromodulation Corporation Stimulation of a stimulation site within the neck or head
US20060206165A1 (en) * 2005-03-14 2006-09-14 Jaax Kristen N Occipital nerve stimulation to treat headaches and other conditions
US8288438B2 (en) 2005-03-21 2012-10-16 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
EP1868587A2 (en) 2005-04-08 2007-12-26 Abbott Laboratories Pharmaceutical formulations comprising fenofibric acid and/or its salts
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
WO2006109156A1 (en) * 2005-04-15 2006-10-19 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
JP2008536928A (ja) * 2005-04-19 2008-09-11 アルザ・コーポレーシヨン トラマドール及び、ガバペンチンを含んでなる物質、の組み合わせ物
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AU2006242154B2 (en) 2005-05-02 2011-11-03 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
WO2006119510A2 (en) * 2005-05-04 2006-11-09 Receptor Biologix, Inc. Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
RU2415858C2 (ru) * 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
EP1919859B1 (en) * 2005-06-20 2010-06-02 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
WO2007002597A2 (en) 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007002867A1 (en) 2005-06-28 2007-01-04 Cv Therapeutics, Inc. Abca1 elevating compounds
JP2009500339A (ja) * 2005-06-29 2009-01-08 アルザ・コーポレーシヨン 浸透性剤形のための低下された乾燥時間を提供する半透過性組成物
US8348930B2 (en) * 2005-07-01 2013-01-08 Microlin, Llc Fluid delivery device with a diffusion membrane and electrochemical pump
EP1904046A4 (en) * 2005-07-06 2008-10-01 Sepracor Inc COMBINATIONS OF ESZOPICLON AND O-DESMETHYLVENLAFAXINE AND METHOD FOR THE TREATMENT OF MENOPAUSE AND HUMOR FLUCTUATIONS; ANXIETY AND COGNITIVE INTERFERENCE
US20070009573A1 (en) * 2005-07-07 2007-01-11 L N K International Method of forming immediate release dosage form
TWI279234B (en) * 2005-07-12 2007-04-21 Anchen Pharmaceuticals Taiwan Method for controlling lag time of in-situ passageway formation in osmotic delivery system
US20070021734A1 (en) * 2005-07-15 2007-01-25 Sai Bhavaraju Bioelectro-osmotic engine fluid delivery device
US20070025869A1 (en) * 2005-07-15 2007-02-01 Gordon John H Fluid Delivery Device
US20070023291A1 (en) * 2005-07-15 2007-02-01 Sai Bhavaraju Metal Trap
WO2007013929A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
US20070031496A1 (en) * 2005-08-04 2007-02-08 Edgren David E Osmotic dosage forms comprising semipermeable membranes with polymer blends providing improved properties
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
EP1959923A4 (en) * 2005-08-30 2012-05-02 Piramal Life Sciences Ltd PHARMACEUTICAL METFORMIN COMPOSITION WITH EXTENDED RELEASE AND METHOD OF PREPARATION THEREOF
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
KR20080042158A (ko) 2005-08-31 2008-05-14 셀진 코포레이션 이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
BRPI0615691A8 (pt) 2005-08-31 2017-08-15 Aryx Therapeutics Inc Método para a preparação de 6-((3s,4r)-4-(4-amino-5-cloro-2-metoxibenzamido)-3-metoxipiperidin-1-il) hexanoato de (r)-quinuclidin-3-ila ou sal do mesmo
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US7684858B2 (en) * 2005-09-21 2010-03-23 Boston Scientific Neuromodulation Corporation Methods and systems for placing an implanted stimulator for stimulating tissue
US20070072838A1 (en) * 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
US7799820B2 (en) * 2005-09-30 2010-09-21 Banyu Pharmaceutical Co., Ltd. 2-Heterocycle-substituted indole derivatives for treating diabetes and associated conditions
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
JP2009511593A (ja) * 2005-10-13 2009-03-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ１アデノシンレセプターアゴニスト
US20070092585A1 (en) * 2005-10-14 2007-04-26 Skinner Michael K Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8629147B2 (en) 2005-11-03 2014-01-14 Chembridge Corporation Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2007132293A2 (en) 2005-11-10 2007-11-22 Circ Pharma Research And Development Limited Once-daily administration of central nervous system drugs
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
WO2007059010A2 (en) 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
CN101312964A (zh) 2005-11-21 2008-11-26 普渡制药公司 4-噁二唑基哌啶化合物及其用途
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
WO2007067495A2 (en) * 2005-12-05 2007-06-14 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP3363455A1 (en) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US7835803B1 (en) 2006-01-17 2010-11-16 Boston Scientific Neuromodulation Corporation Lead assemblies with one or more switching networks
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
TW200806292A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Vinyl-phenyl derivatives for inflammation and immune-related uses
US8455658B2 (en) * 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070254926A1 (en) * 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
KR20080090491A (ko) 2006-02-03 2008-10-08 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ-아데노신 수용체 효능제 및 이의 다형체의 제조 방법
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070196487A1 (en) * 2006-02-16 2007-08-23 Geerke Johan H Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20070201024A1 (en) * 2006-02-28 2007-08-30 Geerke Johan H Method and apparatus for semi-permeable membrane detection on osmotic tablets incorating near-infrared spectroscopy
AU2007225273A1 (en) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
JP2009530280A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド シタクスセンタンナトリウムの配合物
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
PL2383271T3 (pl) * 2006-03-13 2013-12-31 Kyorin Seiyaku Kk Aminochinolony jako inhibitory GSK-3
US8175710B2 (en) * 2006-03-14 2012-05-08 Boston Scientific Neuromodulation Corporation Stimulator system with electrode array and the method of making the same
US20070219174A1 (en) * 2006-03-15 2007-09-20 Pharmacyclics, Inc. Methods of treating cancer using hypofractionated radiation and texaphyrins
US20100273776A1 (en) * 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
US20190083399A9 (en) * 2006-04-03 2019-03-21 Isa Odidi Drug delivery composition
EP2007360B1 (en) 2006-04-03 2014-11-26 Isa Odidi Controlled release delivery device comprising an organosol coat
JP2009535552A (ja) * 2006-04-28 2009-10-01 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 少なくとも１つの帯電可能な材料を有する浸透圧ポンプ
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CA2651732C (en) 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
DK2046393T3 (da) 2006-05-26 2014-05-12 Signature Therapeutics Inc Kontrolleret frigivelse af phenol-opioider
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
US7659287B2 (en) * 2006-06-08 2010-02-09 Amgen Inc. Benzamide derivatives and uses related thereto
NZ574093A (en) * 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
CA2655835C (en) 2006-06-19 2015-07-21 Alpharma, Inc. Abuse-resistant pharmaceutical compositions of opioid agonists
ATE496924T1 (de) 2006-06-22 2011-02-15 Anadys Pharmaceuticals Inc Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
JP5306194B2 (ja) 2006-06-22 2013-10-02 アナディス ファーマシューティカルズ インク ピロ［１，２−ｂ］ピリダジノン化合物
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2007149929A1 (en) * 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders
US8401654B1 (en) 2006-06-30 2013-03-19 Boston Scientific Neuromodulation Corporation Methods and systems for treating one or more effects of deafferentation
US8504163B1 (en) 2006-06-30 2013-08-06 Boston Scientific Neuromodulation Corporation Cranially mounted stimulation systems and methods
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
CA2671197A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
CA2653056A1 (en) 2006-07-27 2008-01-31 Cv Therapeutics, Inc. Aldh-2 inhibitors in the treatment of addiction
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
AU2007293107A1 (en) * 2006-08-04 2008-03-13 Agi Therapeutics Research Limited Methods for treating at least one condition having MT1 receptor, 5HT2GB receptor, and L-type calcium channel activity
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
MX2009001989A (es) 2006-08-30 2009-03-09 Celgene Corp Compuestos de isoindolina 5-substituidos.
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
JP2010502649A (ja) * 2006-09-01 2010-01-28 シーブイ・セラピューティクス・インコーポレイテッド 心筋層画像化法中の患者の耐性を増加させるための方法および組成物
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
BRPI0716952A2 (pt) * 2006-09-15 2013-10-29 Reviva Pharmaceuticals Inc Composto, métodos para tratar e/ou prevenir obesidade ou indicação co-mórbida relacionada à obesidade, e para sintetizar derivado de cicloalquilmetilamina
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2066662B1 (en) 2006-09-21 2012-12-05 Kyorin Pharmaceutical Co., Ltd. Serine hydrolase inhibitors
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
PL2420498T3 (pl) 2006-09-26 2017-10-31 Celgene Corp 5-podstawione pochodne chinazolinonu jako środki przeciwnowotworowe
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
US7445528B1 (en) 2006-09-29 2008-11-04 Boston Scientific Neuromodulation Corporation Connector assemblies
MX2009003658A (es) * 2006-10-05 2009-04-22 Cv Therapeutics Inc Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
CA2666143A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EP2076518A1 (en) * 2006-10-12 2009-07-08 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP5550906B2 (ja) 2006-10-19 2014-07-16 ゲンズイメ コーポレーション 嚢胞性疾患の治療のためのプリン誘導体
AU2007310949A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US7347746B1 (en) 2006-10-27 2008-03-25 Boston Scientific Neuromodulation Corporation Receptacle connector assembly
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
WO2008063504A2 (en) 2006-11-13 2008-05-29 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
EP2096923B1 (en) 2006-11-27 2014-01-22 H. Lundbeck A/S Heteroaryl amide derivatives
WO2008066131A1 (fr) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Nouveau dérivé de phényl-isoxazol-3-ol
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2121705A2 (en) 2006-12-01 2009-11-25 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CA2671286C (en) 2006-12-06 2017-09-19 Spinal Modulation, Inc. Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
WO2008070809A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
US9427570B2 (en) * 2006-12-06 2016-08-30 St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) Expandable stimulation leads and methods of use
AU2007329252A1 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Hard tissue anchors and delivery devices
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
WO2008073452A1 (en) * 2006-12-11 2008-06-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
JP2010512414A (ja) 2006-12-12 2010-04-22 ギリード・コロラド・インコーポレーテッド 肺高血圧を処置するための組成物
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US20080147186A1 (en) * 2006-12-14 2008-06-19 Joshi Ashok V Electrochemical Implant For Delivering Beneficial Agents
US7829592B2 (en) * 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
WO2008076458A1 (en) * 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
KR20090086115A (ko) * 2006-12-22 2009-08-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
US7932421B2 (en) * 2006-12-26 2011-04-26 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
EP2119442A4 (en) 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
PT2076506E (pt) 2007-01-16 2010-12-10 Purdue Pharma Lp Compostos de piperidina substituídos nos grupos heterocíclicos como ligandos orl-1
US20080176955A1 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
CN101678203A (zh) * 2007-01-29 2010-03-24 脊髓调制公司 无缝合线引线保持构造
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
TWI446903B (zh) 2007-02-21 2014-08-01 Sepracor Inc 含（-）-ｏ-去甲基泛拉弗辛（ｖｅｎｌａｆａｘｉｎｅ）之固體形式及其用途
EP2144604B1 (en) 2007-02-28 2011-09-21 Conatus Pharmaceuticals, Inc. Methods for the treatment of chronic viral hepatitis C using RO 113-0830
CL2008000666A1 (es) * 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
TW200909417A (en) * 2007-03-12 2009-03-01 Biolipox Ab Piperidinones useful in the treatment of inflammation
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
TW200846305A (en) 2007-03-15 2008-12-01 Auspex Pharmaceuticals Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
CA2683409A1 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
CA2681560A1 (en) * 2007-04-09 2008-10-16 Cv Therapeutics, Inc. Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
EP2142529B1 (en) 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
NZ579820A (en) 2007-04-27 2011-01-28 Purdue Pharma Lp Therapeutic agents useful for treating pain
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
EP2019101A1 (en) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
NZ580429A (en) 2007-05-31 2012-04-27 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
CN101820757A (zh) 2007-06-01 2010-09-01 普林斯顿大学托管委员会 通过调节宿主细胞代谢途径治疗病毒感染
US20100240713A1 (en) * 2007-06-05 2010-09-23 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
WO2009011988A2 (en) * 2007-06-05 2009-01-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US20080306076A1 (en) * 2007-06-08 2008-12-11 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
ES2601856T3 (es) 2007-06-08 2017-02-16 Mannkind Corporation Inhibidores de la IRE-1A
US9603848B2 (en) * 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090042987A1 (en) * 2007-07-06 2009-02-12 Michael Lionel Selley Treatment of neuropathic pain
CN101801188A (zh) * 2007-07-12 2010-08-11 特拉加拉医药品公司 治疗癌症、肿瘤和肿瘤相关性疾病的方法和组合物
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
CN101754962B (zh) * 2007-07-19 2013-12-25 赛马拜制药公司 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物
TWI444186B (zh) 2007-08-01 2014-07-11 Synta Pharmaceuticals Corp 用於發炎與免疫相關用途之雜環－芳基化合物
US8349841B2 (en) 2007-08-01 2013-01-08 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
LT2194783T (lt) 2007-08-10 2017-10-25 Vm Discovery, Inc. Apoptozės moduliatorių kompozicijos ir būdai
WO2009023718A2 (en) 2007-08-13 2009-02-19 Metabasis Therapeutics, Inc. Novel activators of glucokinase
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
ES2593706T3 (es) 2007-08-31 2016-12-12 Purdue Pharma Lp Compuestos de piperidina, de tipo quinoxalina sustituida, y usos de los mismos
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
MX2010002667A (es) * 2007-09-11 2010-04-01 Activx Biosciences Inc Cianoaminoquinolonas y tetrazoloaminoquinolonas como inhibidores de gsk-3.
BRPI0816814B1 (pt) 2007-09-12 2021-08-31 Kyorin Pharmaceutical Co. Ltd Composto, composição farmacêutica e uso de um composto
CZ300468B6 (cs) * 2007-09-20 2009-05-27 Zentiva, A. S Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
CN101952272B (zh) 2007-09-26 2014-08-27 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
AR068540A1 (es) * 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
KR20100082775A (ko) * 2007-10-16 2010-07-19 심포젠 에이/에스 최적화된 ｈｅｒ1 및 ｈｅｒ3 멀티머를 포함하는 조성물 및 그것의 사용 방법
WO2009052454A2 (en) 2007-10-19 2009-04-23 University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
CA2705370C (en) 2007-11-12 2015-10-13 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy quinazoline derivatives
DK2596784T3 (en) 2007-11-23 2017-03-06 Gruenenthal Gmbh Tapentadol compositions
CA2706931C (en) 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090162417A1 (en) * 2007-12-21 2009-06-25 Cook Incorporated Drug eluting ocular conformer
US20100261699A1 (en) 2007-12-25 2010-10-14 Banyu Pharmaceutical Co., Ltd. N-pyrazole-2-pyridine carboxamide derivative
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
WO2009100326A1 (en) * 2008-02-07 2009-08-13 Cv Therapeutics, Inc. Abca-1 elevating compounds and the use thereof
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
US8618289B2 (en) 2008-03-17 2013-12-31 Ambit Biosciences Corporation RAF kinase modulator compounds and methods of use thereof
MX2010010272A (es) 2008-03-19 2011-05-25 Chembridge Corp Nuevos inhibidores de tirosina quinasa.
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
KR20150038547A (ko) 2008-03-27 2015-04-08 셀진 코포레이션 (+)-2-[1-(3-에톡시-4-메톡시페닐)-2-메틸설포닐에틸]-4-아세틸아미노이소인돌린-1,3-디온을 포함하는 고체 형태, 이의 조성물, 및 이의 용도
US20090270404A1 (en) * 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
SG189714A1 (en) 2008-04-01 2013-05-31 Antipodean Pharmaceuticals Inc Compositions and methods for skin care
CA2719288A1 (en) * 2008-04-04 2009-11-12 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors
CN103381267A (zh) 2008-04-14 2013-11-06 哈洛齐梅公司 修饰的透明质酸酶及其在治疗透明质酸相关疾病和病症中的应用
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
BRPI0912842A8 (pt) * 2008-05-20 2019-01-29 Cerenis Therapeutics Holding composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
US8207163B2 (en) * 2008-05-27 2012-06-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using piperazine based antipsychotic agents
EP2298750A4 (en) 2008-06-02 2012-04-25 Msd Kk NOVEL ISOXAZOLE DERIVATIVE
US8894602B2 (en) 2010-09-17 2014-11-25 Johnson & Johnson Vision Care, Inc. Punctal plugs with directional release
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
ES2458358T3 (es) 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
AR072578A1 (es) 2008-07-21 2010-09-08 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos
NZ588311A (en) * 2008-07-24 2012-08-31 Handa Pharmaceuticals Llc Stabilized atypical antipsychotic formulation to treat psychiatric conditions
WO2010014229A1 (en) 2008-07-30 2010-02-04 Purdue Pharma L.P. Buprenorphine analogs
RU2511315C2 (ru) 2008-07-31 2014-04-10 Синомикс, Инк. Композиции, содержащие усилители сладкого вкуса, и способы их получения
WO2010014666A2 (en) 2008-07-31 2010-02-04 Senomyx, Inc. Processes and intermediates for making sweet taste enhancers
EP2326618B1 (en) 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Glucagon antagonists
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
CA2739322A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
AU2009302241B2 (en) 2008-10-08 2015-10-29 Xgene Pharmaceutical Inc. GABA conjugates and methods of use thereof
WO2010042834A1 (en) 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
EP3135672B9 (en) 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
CN102186804A (zh) * 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010062622A2 (en) 2008-10-27 2010-06-03 Spinal Modulation, Inc. Selective stimulation systems and signal parameters for medical conditions
SI2358697T1 (sl) 2008-10-29 2016-02-29 Celgene Corporation Spojine izoindolina za uporabo pri zdravljenju raka
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
CN104257600A (zh) 2008-10-30 2015-01-07 格吕伦塔尔有限公司 新型有效的他喷他多剂型
WO2010056527A2 (en) 2008-10-30 2010-05-20 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
BRPI0921625A2 (pt) 2008-11-04 2016-01-05 Univ Kentucky Res Foundation Inc composicoes baseadas em d-tagatose e metodos para previnir e tratar aterosclerose, sindrome metabolica, e sintomas dos mesmos
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
BRPI0922224A2 (pt) 2008-12-08 2016-08-02 Vm Pharma Llc composições de inibidores de proteína tirosina quiinase receptora.
ES2724588T3 (es) 2008-12-09 2019-09-12 Halozyme Inc Polipéptidos de PH20 soluble extendida y usos de los mismos
AU2009330355B2 (en) 2008-12-16 2016-06-30 Sunovion Pharmaceuticals Inc. Triple reuptake inhibitors and methods of their use
EP2376633A1 (en) 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
AU2009330192A1 (en) 2008-12-22 2011-07-14 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
US20110306605A1 (en) 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
WO2010080835A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
KR20170005192A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
CN102341105B (zh) 2009-02-03 2014-09-17 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
CN102340992B (zh) 2009-02-09 2014-11-05 桑诺维恩药品公司 吡咯烷三重再摄取抑制剂
CA2750123A1 (en) 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
CN102388043A (zh) 2009-02-11 2012-03-21 桑诺维恩药品公司 组胺h3反相激动剂和拮抗剂及其使用方法
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
US20110275647A1 (en) 2009-02-23 2011-11-10 Msd K.K. Pyrimidin-4-(3h)-one derivatives
BRPI1008280A2 (pt) 2009-02-24 2015-08-25 Ritter Pharmaceuticals Inc Formulações prebióticas e métodos mde uso
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
KR101705727B1 (ko) 2009-02-26 2017-02-10 레비바 파마슈티칼스, 아이엔씨. 아릴피페라진 유도체의 조성물, 합성, 및 사용 방법
CN102395576A (zh) * 2009-02-27 2012-03-28 埃姆比特生物科学公司 调控jak激酶的喹唑啉衍生物和其使用方法
US8193372B2 (en) 2009-03-04 2012-06-05 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole HCV polymerase inhibitors
CA2754461A1 (en) * 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 and uses thereof
UY32487A (es) 2009-03-10 2010-06-30 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
AU2010221990B2 (en) * 2009-03-11 2015-06-04 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as GSK-3 inhibitors
EP2406248B1 (en) 2009-03-11 2013-12-25 Msd K.K. Novel isoindolin-1-one derivative
CN102448458B (zh) 2009-03-18 2015-07-22 小利兰·斯坦福大学理事会 治疗黄病毒科病毒感染的方法和组合物
JP2012521801A (ja) 2009-03-24 2012-09-20 スパイナル・モデュレーション・インコーポレイテッド 錯感覚に対する閾値以下の刺激を伴う疼痛の管理
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CN102481276A (zh) 2009-04-20 2012-05-30 埃尔舍利克斯治疗公司 基于化学感受受体配体的治疗法
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN102459210B (zh) 2009-04-22 2015-09-02 埃克希金医药品有限公司 芳基磺酰胺ccr3拮抗剂
BRPI1014669A2 (pt) 2009-04-22 2017-07-18 Axikin Pharmaceuticals Inc antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída
NZ595797A (en) 2009-04-22 2014-03-28 Axikin Pharmaceuticals Inc 2,5-disubstituted arylsulfonamide ccr3 antagonists
WO2010127452A1 (en) 2009-05-04 2010-11-11 The Royal Institution For The Advancement Of Learning/Mcgill University 5-oxo-ete receptor antagonist compounds
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
AU2010248802B2 (en) 2009-05-15 2017-02-02 Spinal Modulation, Inc. Methods, systems and devices for neuromodulating spinal anatomy
EP2432455B1 (en) 2009-05-18 2014-11-12 Sigmoid Pharma Limited Composition comprising oil drops
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
US8956654B2 (en) 2009-06-02 2015-02-17 Dow Global Technologies Llc Sustained release dosage form
JP2012529529A (ja) 2009-06-10 2012-11-22 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
AU2010260208B2 (en) 2009-06-16 2014-11-13 Bristol-Myers Squibb Holdings Ireland Unlimited Company Dosage forms of apixaban
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP3072890B1 (en) 2009-07-07 2018-10-17 MEI Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
HUE035519T2 (en) 2009-07-08 2018-05-02 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical composition
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2467144A1 (en) 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
PL2464645T3 (pl) 2009-07-27 2017-12-29 Gilead Sciences, Inc. Skondensowane heterocykliczne związki jako modulatory kanałów jonowych
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
CA2770570A1 (en) 2009-08-12 2011-02-17 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20110039799A1 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
CA2770454A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US20120190743A1 (en) 2009-09-04 2012-07-26 United Paragon Associates Inc. Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
MX2012002898A (es) 2009-09-11 2012-04-02 Sunovion Pharmaceuticals Inc Agonistas y antagonistas inversos de histamina h3 y metodos de uso para los mismos.
CN102666553B (zh) * 2009-10-01 2015-05-06 赛马拜制药公司 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
US20110136751A1 (en) 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
US20110082198A1 (en) * 2009-10-07 2011-04-07 Jiangsu Dehe Bio-Tech Co., Ltd. Theaflavin compositions, production, and methods to control physiological disorders in mammals
US8282970B2 (en) * 2009-10-07 2012-10-09 Jiahgsu Dehe Bio-Tech Co., Ltd Theaflavin compositions, related processes and methods of use
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RU2015103694A (ru) 2009-10-14 2015-06-27 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
KR20120093970A (ko) 2009-10-19 2012-08-23 신타 파마슈티칼스 코프. 에이취에스피90 억제 화합물을 이용한 조합 항암 요법
WO2011056566A2 (en) 2009-10-26 2011-05-12 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
ES2565644T3 (es) 2009-11-09 2016-04-06 Xenoport, Inc. Composiciones farmacéuticas y formas de dosificación oral de un pre medicamento de levodopa y los métodos de utilización
KR101769637B1 (ko) 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011063102A1 (en) 2009-11-19 2011-05-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
SG181498A1 (en) 2009-12-04 2012-07-30 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
KR101755743B1 (ko) 2009-12-04 2017-07-07 선오비온 파마슈티컬스 인코포레이티드 트랜스노르세르트랄린의 제형, 염 및 다형체, 및 이들의 용도
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
CA2783616A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
IN2012DN04858A (hr) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
US20120010131A1 (en) 2009-12-30 2012-01-12 Scynexis, Inc. Novel cyclosporin analogues
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CA2786266A1 (en) 2010-01-05 2011-07-14 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
WO2011089166A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
WO2011091164A1 (en) * 2010-01-22 2011-07-28 Xenoport, Inc. Oral dosage forms having a high loading of a tranexamic acid prodrug
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
WO2011097525A1 (en) 2010-02-05 2011-08-11 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
US8471041B2 (en) * 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
EP4289838A3 (en) 2010-02-11 2024-03-13 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
MX343215B (es) 2010-02-26 2016-10-27 Xenon Pharmaceuticals Inc Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
HUE025699T2 (en) 2010-03-02 2016-04-28 Axikin Pharmaceuticals Inc Isotopically enriched arylsulfonamide derivatives as CCR3 antagonists
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
JP2013522236A (ja) 2010-03-12 2013-06-13 セルジーン コーポレイション レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー
MX336559B (es) 2010-03-17 2016-01-25 Axikin Pharmaceuticals Inc Antagonistas de ccr3 de arilsulfonamida.
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
JP2013525281A (ja) 2010-04-05 2013-06-20 マンカインド コーポレ−ション ＩＲＥ−１αインヒビター
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
CN102884072A (zh) 2010-04-08 2013-01-16 爱默蕾大学 被取代的雄甾-4-烯二酮
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20130156755A1 (en) 2010-04-19 2013-06-20 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
CA2798961A1 (en) 2010-05-10 2011-11-17 Spinal Modulation, Inc. Methods, systems and devices for reducing migration
WO2011146803A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
WO2011149824A1 (en) 2010-05-24 2011-12-01 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
MX351368B (es) 2010-05-26 2017-10-12 Sunovion Pharmaceuticals Inc Compuestos heteroarilo y metodos para utilizarlos.
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
WO2011153199A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
CA2801001A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
CA2801778C (en) 2010-06-07 2018-06-05 Novomedix, Llc Furanyl compounds and the use thereof
ES2526124T3 (es) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
BR112012032248A2 (pt) 2010-06-23 2016-09-13 Metabolex Inc composições de 5-etil-2-{4-[-4(-4-tetrazol-1-il-fenoximetil)-tiazol-2-il]-piperidin-1-il}-pirimidina
CA2802891A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of a2b adenosine receptor antagonists for treating pulmonary hypertension
MX2012015105A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Inhibidores de cinasa de regulacion mediante señal de apoptosis.
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
AR082189A1 (es) 2010-07-06 2012-11-21 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas, procedimiento
US20120015031A1 (en) 2010-07-14 2012-01-19 Grunenthal Gmbh Novel gastro-retentive dosage forms
US20130178522A1 (en) 2010-07-19 2013-07-11 James M. Jamison Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
BR112013003332B1 (pt) 2010-08-12 2018-11-13 Senomyx, Inc. método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado
DK2608782T3 (en) 2010-08-24 2016-09-05 Algiax Pharmaceuticals Gmbh New use of leflunomide malononitrilamider
WO2012030668A1 (en) 2010-08-30 2012-03-08 SinuSys Corporation Device and kit for inserting a sinus dilator
EP2611502A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
JP5932794B2 (ja) 2010-09-01 2016-06-08 アムビト ビオスシエンセス コルポラチオン 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
US20130303533A1 (en) 2010-09-01 2013-11-14 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
CA2809983A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
AU2011302344B2 (en) 2010-09-13 2015-01-15 Synta Pharmaceuticals Corp. HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
WO2012050922A2 (en) 2010-09-28 2012-04-19 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
BR112013008983A2 (pt) 2010-10-15 2016-07-05 Gilead Sciences Inc composições e métodos de tratamento da hipertensão pulmonar
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
MX337179B (es) 2010-10-18 2016-02-15 Cerenis Therapeutics Holding Sa Compuestos, composiciones y metodos utiles para la movilizacion de colesterol.
CN104220875A (zh) 2010-10-19 2014-12-17 埃尔舍利克斯治疗公司 基于化学感应受体配体的治疗
ES2655084T3 (es) 2010-10-29 2018-02-16 Algiax Pharmaceuticals Gmbh Empleo de malononitrilamidas en dolor neuropático
EP2638032A1 (en) 2010-11-09 2013-09-18 Synta Pharmaceuticals Corp. Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
RU2013127625A (ru) 2010-11-18 2014-12-27 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
EP2648676A4 (en) 2010-12-06 2016-05-04 Follica Inc METHODS FOR TREATING CALVITIA AND PROMOTING HAIR GROWTH
US20140031325A1 (en) 2010-12-06 2014-01-30 Celgene Corporation Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
US20140005145A1 (en) 2010-12-08 2014-01-02 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US20120157938A1 (en) 2010-12-16 2012-06-21 Tokarski Jason M Punctal plug with drug core retention features
MX354210B (es) 2010-12-16 2018-02-16 Celgene Corp Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
DK2826467T3 (en) 2010-12-22 2017-10-16 Purdue Pharma Lp INCLUDED, MANIPULATION-PROPOSED SLOW-DELIVERY DOSAGE FORMS
AU2011346749A1 (en) 2010-12-22 2013-05-02 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
CN107412173A (zh) 2010-12-23 2017-12-01 普渡制药公司 抗篡改固体口服剂型
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
US8853175B2 (en) 2011-01-10 2014-10-07 Celgene Corporation Phenethylsulfone isoindoline derivatives and their use
MX2013007959A (es) 2011-01-10 2013-12-06 Celgene Corp Formas farmaceuticas orales de amida {2-[(1s)-1-(3-etoxi-4-metoxi- fenil]-2-metansulfonil-etil]-3-oxo-2,,3-dihidro-1h-isoindol -4-il}-del acido ciclopropancarboxilico.
BR112013017670B1 (pt) 2011-01-10 2022-07-19 Infinity Pharmaceuticals, Inc Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas
WO2012096919A1 (en) 2011-01-11 2012-07-19 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
CN103619841B (zh) 2011-01-11 2017-03-29 桑诺维恩药品公司 杂芳基化合物及其使用方法
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
HUE026715T2 (en) 2011-01-20 2016-07-28 Bionevia Pharmaceuticals Inc Modified release pharmaceutical composition comprising Epalrestat or a derivative thereof and methods of their use
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
CA2825763A1 (en) 2011-02-02 2012-08-09 Spinal Modulation, Inc. Devices, systems and methods for the targeted treatment of movement disorders
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
WO2012116061A1 (en) 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
JP2014507443A (ja) 2011-02-24 2014-03-27 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０阻害化合物での前立腺癌治療
WO2012116247A1 (en) 2011-02-25 2012-08-30 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
EP2683376B1 (en) 2011-03-07 2018-11-28 Celgene Corporation Methods for treating diseases using isoindoline compounds
PE20140983A1 (es) 2011-03-11 2014-08-25 Celgene Corp Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
HUE027481T2 (en) 2011-03-11 2016-09-28 Celgene Corp Methods of treating cancer with 3- (5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl) -piperidine-2,6-dione
US20140057978A1 (en) 2011-03-17 2014-02-27 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
WO2012123406A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of imidazotriazinones
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
TWI572599B (zh) 2011-03-28 2017-03-01 Ｍｅｉ製藥公司 （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途
AU2012236722A1 (en) 2011-03-28 2013-10-17 Mei Pharma, Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US9090585B2 (en) 2011-03-28 2015-07-28 Deuterx, Llc 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012158271A1 (en) 2011-04-06 2012-11-22 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds as antiviral agents
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
BR112013027034A8 (pt) 2011-04-21 2018-01-02 Curemark Llc "compostos para o tratamento de transtornos neuropsiquiátricos."
CN103635188B (zh) 2011-04-28 2017-03-22 细胞基因公司 使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物
KR20140024914A (ko) 2011-04-29 2014-03-03 셀진 코포레이션 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
US9604978B2 (en) 2011-05-03 2017-03-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US9480696B2 (en) 2011-05-04 2016-11-01 Trustees Of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US9301874B2 (en) 2011-05-06 2016-04-05 Johnson & Johnson Vision Care, Inc. Punctal plugs for controlled release of therapeutic agents
MX361350B (es) 2011-05-10 2018-12-04 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal de sodio.
US20140315943A1 (en) 2011-05-24 2014-10-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
SG195288A1 (en) 2011-06-07 2013-12-30 Anadys Pharmaceuticals Inc [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2012175698A1 (en) 2011-06-23 2012-12-27 Université Libre de Bruxelles Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
NO3175985T3 (hr) 2011-07-01 2018-04-28
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
TW201837023A (zh) 2011-07-01 2018-10-16 美商基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
DE102011051653A1 (de) * 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
EP2729144A2 (en) 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
EP2741760A2 (en) 2011-08-12 2014-06-18 B.S.R.C. "Alexander Fleming" Tnf superfamily trimerization inhibitors
WO2013028505A1 (en) 2011-08-19 2013-02-28 Synta Pharmaceuticals Corp. Combination cancer therapy of hsp90 inhibitor with antimetabolite
ES2544845T3 (es) 2011-08-23 2015-09-04 Cornerstone Therapeutics Inc. Uso de zileutón en el tratamiento de pólipos nasales en pacientes con fibrosis quística
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
TWI468403B (zh) 2011-08-30 2015-01-11 Gilead Sciences Inc 用於治療成癮之ａｌｄｈ－２抑制劑
WO2013033636A2 (en) 2011-09-01 2013-03-07 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
AU2012308900A1 (en) 2011-09-12 2013-05-09 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
CA2849505A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
CN104114182A (zh) 2011-09-23 2014-10-22 细胞基因公司 罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用
KR20140069271A (ko) 2011-09-26 2014-06-09 셀진 코포레이션 화학요법 내성 암에 대한 병용 요법
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
EP2764406B1 (en) 2011-10-07 2018-03-14 Cedars-Sinai Medical Center Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
WO2013052164A1 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Organonitro thioether compounds and medical uses thereof
EP2766041B1 (en) 2011-10-12 2018-12-05 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
JP6162130B2 (ja) 2011-10-14 2017-07-12 アムビト ビオスシエンセス コルポラチオン Ｉｉｉ型受容体チロシンキナーゼの調節因子としての複素環式化合物及びその使用
TW201331221A (zh) 2011-10-14 2013-08-01 Idenix Pharmaceuticals Inc 嘌呤核苷酸化合物類之經取代的３’，５’－環磷酸酯及用於治療病毒感染之醫藥組成物
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
CN104168884A (zh) 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法
TWI615155B (zh) 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
US9243037B2 (en) 2011-11-10 2016-01-26 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
AU2012324015A1 (en) 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
MX349036B (es) 2011-12-06 2017-07-07 Univ Leland Stanford Junior Metodos y composiciones para tratar enfermedades virales.
JP5946921B2 (ja) 2011-12-08 2016-07-06 パーデュー、ファーマ、リミテッド、パートナーシップ 四級化ブプレノルフィン類似体
CA2859173A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
EP2809656A2 (en) 2011-12-28 2014-12-10 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
ES2851602T3 (es) 2011-12-28 2021-09-08 Allergan Inc Derivados de 3-fenil-5-ureidoisotiazol-4-carboxamida como inhibidores de cinasa
WO2013101926A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
DK2797622T3 (en) 2011-12-30 2017-01-16 Halozyme Inc PH20 polypeptide variants, formulations and uses thereof
EP2797870B1 (en) 2011-12-30 2019-02-20 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using 1-[1-phenyl-cyclobutyl]isobutylamine derivatives
MX351313B (es) 2012-01-05 2017-10-10 Boston Medical Ct Corp Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón.
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
AU2012363873B2 (en) 2012-01-06 2017-11-23 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
AU2013203252B2 (en) 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
AU2013216935C1 (en) 2012-02-08 2017-12-14 John Emmerson Campbell Heteroaryl compounds and methods of use thereof
EP2817300B1 (en) 2012-02-21 2018-04-25 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
TWI635855B (zh) 2012-02-29 2018-09-21 壯生和壯生視覺關懷公司 具有激能圍阻陣列之淚管塞
WO2013130468A1 (en) 2012-02-29 2013-09-06 SinuSys Corporation Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
SG10201507714XA (en) 2012-03-16 2015-10-29 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CA2901394A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
EP2830616A1 (en) 2012-03-27 2015-02-04 Incuron LLC Curaxins for use in treating breast cancer and method for identifying patients likely to respond
WO2013148857A1 (en) 2012-03-28 2013-10-03 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
JP2015515477A (ja) 2012-04-04 2015-05-28 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節する新規トリアゾール化合物
RS57449B1 (sr) 2012-04-04 2018-09-28 Halozyme Inc Kombinovana terapija sa hijaluronidazom i taksanom koji ciljno deluje na tumor
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
EP3485880A1 (en) 2012-04-17 2019-05-22 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
ES2656292T3 (es) 2012-05-01 2018-02-26 Translatum Medicus Inc. Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera
WO2013170159A1 (en) 2012-05-10 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
TW201408645A (zh) 2012-05-11 2014-03-01 Purdue Pharma Lp 苯並嗎凡類似物及其用途
US9074972B2 (en) 2012-05-16 2015-07-07 Dionex Corporation Surrogate addition device and a method of analyte concentration
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852603B1 (en) 2012-05-22 2021-05-12 Idenix Pharmaceuticals LLC D-amino acid compounds for liver disease
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
JP6427097B2 (ja) 2012-06-15 2018-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 癌を処置するための組成物および該組成物を製造するための方法
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014014427A1 (en) 2012-07-16 2014-01-23 Mahmut Bilgic Modified release pharmaceutical tablet formulations
BR112015000867A2 (pt) 2012-07-16 2019-10-15 Rhodes Tech processo para síntese melhorada de opioide.
EP2872516B1 (en) 2012-07-16 2017-08-30 Rhodes Technologies Process for improved opioid synthesis
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US10513540B2 (en) 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
RU2666534C2 (ru) 2012-08-06 2018-09-11 Сеномикс, Инк. Модификатор сладкого вкуса и аромата
AU2013299631B2 (en) 2012-08-09 2017-09-28 Celgene Corporation Salts and solid forms of (S)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
PL2882442T3 (pl) 2012-08-09 2021-12-13 Celgene Corporation Sposoby leczenia nowotworów z wykorzystaniem 3-(4-((4-(morfolinometylo)benzylo)oksy)-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu
PL2882441T3 (pl) 2012-08-09 2020-09-21 Celgene Corporation Leczenie chorób immunologicznych i zapalnych
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US10624859B2 (en) 2012-08-20 2020-04-21 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
WO2014031465A1 (en) 2012-08-22 2014-02-27 Merck Sharp & Dohme Corp. Novel azabenzimidazole tetrahydropyran derivatives
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
CA2922849A1 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
CN104781240A (zh) 2012-09-07 2015-07-15 埃克希金医药品有限公司 同位素富集的芳基磺酰胺ccr3拮抗剂
EA201590535A1 (ru) 2012-09-10 2015-07-30 Селджин Корпорейшн Способы лечения локально прогрессирующего запущенного рака молочной железы
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
CN111848711A (zh) 2012-10-08 2020-10-30 埃迪尼克斯医药有限责任公司 用于hcv感染的2′-氯核苷类似物
BR112015008118A2 (pt) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc reforço da resposta imune
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
TR201812261T4 (tr) 2012-11-01 2018-11-21 Infinity Pharmaceuticals Inc Pi3 ki̇naz i̇zoform modülatörleri̇ i̇le kanser tedavi̇si̇
EP2916830A2 (en) 2012-11-08 2015-09-16 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US20150290171A1 (en) 2012-11-09 2015-10-15 Celgene Corporation Methods for the treatment of bone loss
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US20140140951A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Rp-Nucleoside Analog
US9670230B2 (en) 2012-11-29 2017-06-06 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
MX370519B (es) 2012-11-30 2019-12-17 Novomedix Llc Sulfonamidas con sustitucion biarilo y su uso.
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2014091298A2 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
EP2931724B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonemorphinan analogs and biological activity on opioid receptors
ES2621305T3 (es) 2012-12-14 2017-07-03 Purdue Pharma Lp Morfinanos espirocíclicos y su uso
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
US8895743B2 (en) 2012-12-21 2014-11-25 Map Pharmaceuticals, Inc. Methysergide derivatives
BR112015014585A2 (pt) 2012-12-21 2017-07-11 Gilead Calistoga Llc composto, composição farmacêutica, e, método de tratamento de um ser humano
US9029384B2 (en) 2012-12-21 2015-05-12 Gilead Calistoga, LLC. Phosphatidylinositol 3-kinase inhibitors
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102593A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
TW201441198A (zh) 2012-12-28 2014-11-01 Purdue Pharma Lp ７，８－環嗎啡喃類似物
CA2896871A1 (en) 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
MX2015008625A (es) 2013-01-05 2015-09-23 Elcelyx Therapeutics Inc Composicion de liberacion demorada que comprende biguanida.
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
WO2014110127A1 (en) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
PE20151431A1 (es) 2013-01-09 2015-09-23 Edgemont Pharmaceuticals Llc Formulaciones de lorazepam de liberacion controlada
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
WO2014110305A1 (en) 2013-01-11 2014-07-17 Mayo Foundation For Medical Education And Research Vitamins c and k for treating polycystic diseases
WO2014110558A1 (en) 2013-01-14 2014-07-17 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US20150342946A1 (en) 2013-01-30 2015-12-03 Pharmorx Therapeutics, Inc. Treatments For Depression And Other Diseases With A Low Dose Agent
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
AU2014215478B2 (en) 2013-02-05 2018-09-13 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
KR20150119254A (ko) 2013-02-15 2015-10-23 알러간, 인코포레이티드 지속된 약물 전달 임플란트
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
NZ628320A (en) 2013-03-14 2017-04-28 Celgene Corp Treatment of psoriatic arthritis using apremilast
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
ES2687958T3 (es) 2013-03-15 2018-10-30 The Regents Of The University Of California Fosfonato diésteres de nucleósido acíclico
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
JP2016514459A (ja) 2013-03-15 2016-05-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 線維素溶解についての二重反応性の強力なクニッツ阻害剤
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
MX2015013912A (es) 2013-04-02 2016-08-12 Celgene Corp Metodos y composiciones que utilizan 4-amino-2-(2,6-dioxo-piperidi n-3-il)-isoindolin-1,3-diona para tratamiento y manejo de canceres en el sistema nervioso central.
WO2014168973A2 (en) 2013-04-08 2014-10-16 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9687263B2 (en) 2013-05-30 2017-06-27 SinuSys Corporation Devices and methods for inserting a sinus dilator
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP3004396B1 (en) 2013-06-06 2019-10-16 The General Hospital Corporation Compositions for the treatment of cancer
WO2014201143A1 (en) 2013-06-11 2014-12-18 President And Fellows Of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
AU2014278011B2 (en) 2013-06-14 2020-03-19 Alyssum Therapeutics, Inc. Lipid-based platinum compounds and nanoparticles
EA028319B1 (ru) 2013-06-14 2017-11-30 Джилид Калистога Ллс Ингибиторы фосфатидилинозитол-3-киназы
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
ES2703623T3 (es) 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
US9333208B2 (en) 2013-07-16 2016-05-10 Movses H. Karakossian HCN inhibitors affecting ganglion cell function and visual function
UA116567C2 (uk) 2013-07-23 2018-04-10 Євро-Селтік С.А. Комбінація оксикодону та налоксону для застосування в лікуванні болю у пацієнтів, які страждають від болю та захворювання, що призводить до дисбактеріозу кишечнику та/або підвищує ризик кишкової бактеріальної транслокації
MX2016001427A (es) 2013-07-31 2016-08-03 Gilead Sciences Inc Inhibidores de syk.
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CA2919602C (en) 2013-08-02 2018-03-13 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone
EP3036226B1 (en) 2013-08-22 2020-01-08 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
EP3038625A4 (en) 2013-08-29 2017-08-23 Trustees of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
CN105683182A (zh) 2013-08-30 2016-06-15 埃姆比特生物科学公司 联芳基乙酰胺化合物及其使用方法
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US20160213659A1 (en) 2013-09-24 2016-07-28 George Sylvestre Treatment of burn pain by trpv1 modulators
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MY175778A (en) 2013-10-04 2020-07-08 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061091A1 (en) 2013-10-21 2015-04-30 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en) 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
ES2909014T3 (es) 2013-11-26 2022-05-04 Brigham & Womens Hospital Inc Composiciones y métodos para modular una respuesta inmunitaria
EP3074389B1 (en) 2013-11-26 2019-08-14 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
MX2016007311A (es) 2013-12-04 2016-09-07 Gilead Sciences Inc Metodos para tratar canceres.
WO2015089321A2 (en) 2013-12-11 2015-06-18 The General Hospital Corporation Use of mullerian inhibiting substance (mis) proteins for contraception and ovarian reserve preservation
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
ES2691541T3 (es) 2013-12-19 2018-11-27 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
EP3082840B1 (en) 2013-12-20 2021-03-24 The General Hospital Corporation Methods and assays relating to circulating tumor cells
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087079B1 (en) 2013-12-26 2019-04-03 Purdue Pharma LP Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
US9994571B2 (en) 2013-12-26 2018-06-12 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
US9902726B2 (en) 2013-12-30 2018-02-27 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
MX2016009125A (es) 2014-01-15 2017-02-02 Rhodes Tech Proceso para la sintesis mejorada de oximorfona.
ES2733552T3 (es) 2014-01-24 2019-11-29 Celgene Corp Procedimientos para el tratamiento de la obesidad mediante apremilast
CN106029614B (zh) 2014-02-05 2019-05-31 Vm肿瘤药物有限责任公司 化合物的组合物及其用途
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015138420A1 (en) 2014-03-10 2015-09-17 Kadmon Corporation, Llc Treatment of brain and central nervous system tumors
EP3119744B1 (en) 2014-03-18 2019-03-06 Algiax Pharmaceuticals GmbH 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
PT3119762T (pt) 2014-03-20 2021-08-31 Capella Therapeutics Inc Derivados de benzimidazole como inibidores de tirosina quinase erbb para o tratamento do cancro
WO2015143161A1 (en) 2014-03-20 2015-09-24 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US20150283149A1 (en) 2014-04-02 2015-10-08 Gilead Sciences, Inc. Methods of treating patients having implantable cardiac devices
JP2017513931A (ja) 2014-04-03 2017-06-01 インビクタス オンコロジー ピーヴィティー．リミテッド 超分子コンビナトリアル治療薬
EP3125905A4 (en) 2014-04-04 2017-11-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
US10106549B2 (en) 2014-04-09 2018-10-23 Siteone Therapeutics, Inc. 10′,11′-modified saxitoxins useful for the treatment of pain
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
WO2015164364A2 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
KR20160147912A (ko) 2014-04-25 2016-12-23 존슨 앤드 존슨 비젼 케어, 인코포레이티드 활성제 방출 시스템에 대한 방법 및 활성제 방출 시스템을 갖는 안과용 디바이스
EP3134733B1 (en) 2014-04-25 2020-10-14 The Brigham and Women's Hospital, Inc. Assay and method for treating subjects with immune-mediated diseases
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
KR20170015312A (ko) 2014-05-12 2017-02-08 코나터스 파마슈티칼스, 인크. 카스파제 억제제를 사용한 만성 간질환의 합병증의 치료
ES2751773T3 (es) 2014-05-15 2020-04-01 Amgen Europe Gmbh Uso de inhibidores pde4 y combinaciones de los mismos para el tratamiento de la fibrosis quística
EP3142663A1 (en) 2014-05-16 2017-03-22 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US11021435B2 (en) 2014-05-19 2021-06-01 Northeastern University Serotonin receptor-targeting compounds and methods
EP3145500A1 (en) 2014-05-23 2017-03-29 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
CA2947939A1 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CA2952044C (en) 2014-06-13 2019-01-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
AU2015277786B2 (en) 2014-06-19 2019-04-18 Takeda Pharmaceutical Company Limited Heteroaryl compounds for kinase inhibition
ES2749433T3 (es) 2014-06-23 2020-03-20 Celgene Corp Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
EP3160486B1 (en) 2014-06-27 2020-11-18 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
NZ726365A (en) 2014-07-14 2018-06-29 Gilead Sciences Inc Combinations for treating cancers
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CA2956256A1 (en) 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10092541B2 (en) 2014-08-15 2018-10-09 Celgene Corporation Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
RS64038B1 (sr) 2014-08-22 2023-04-28 Celgene Corp Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
PL3186281T3 (pl) 2014-08-28 2019-10-31 Halozyme Inc Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
EP3185910A4 (en) 2014-08-29 2018-01-10 Children's Medical Center Corporation Methods and compositions for the treatment of cancer
US20170319548A1 (en) 2014-09-12 2017-11-09 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
EP3193872A4 (en) 2014-09-14 2018-02-28 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
SG11201701957XA (en) 2014-09-15 2017-04-27 Univ California Nucleotide analogs
WO2016044707A1 (en) 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
ES2727376T3 (es) 2014-09-26 2019-10-15 Gilead Sciences Inc Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
CA2965169C (en) 2014-10-21 2021-11-16 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
PL3215127T3 (pl) 2014-11-07 2021-05-17 Sublimity Therapeutics Limited Kompozycje zawierające cyklosporynę
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
SG11201704791WA (en) 2014-12-16 2017-07-28 Celgene Corp Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107250116B (zh) 2014-12-23 2020-10-27 艾士盟医疗公司 3,5-二氨基吡唑激酶抑制剂
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP2018502157A (ja) 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ，インコーポレイティド アルツハイマー病の治療方法
EP3244896B1 (en) 2015-01-12 2024-06-12 Reviva Pharmaceuticals, Inc. Methods for treating pulmonary hypertension
AU2016206682B2 (en) 2015-01-14 2021-11-11 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-LAP monoclonal antibodies
AU2016209490B2 (en) 2015-01-20 2020-09-03 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
EP3253753A4 (en) 2015-01-20 2018-06-27 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
US11497733B2 (en) 2015-02-09 2022-11-15 Synta Pharmaceuticals Corp. Combination therapy of HSP90 inhibitors and PD-1 inhibitors for treating cancer
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
CN107660207B (zh) 2015-03-10 2020-09-29 罗德科技公司 丁丙诺啡乙酸盐及用于制备丁丙诺啡的方法
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
WO2016172479A1 (en) 2015-04-22 2016-10-27 Cedars-Sinai Medical Center Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
CN108368147A (zh) 2015-05-27 2018-08-03 南方研究院 用于治疗癌症的核苷酸
WO2016196664A1 (en) 2015-06-01 2016-12-08 Cedars-Sinai Medical Center Methods and use of compounds that bind to rela of nf-kb
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
SI3313818T1 (sl) 2015-06-26 2024-03-29 Celgene Corporation Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
PT3456717T (pt) 2015-07-06 2021-05-26 Gilead Sciences Inc Derivado de 4,6-diamino-quinolina-3-carbonitrilo como modulador do cancro da tiróide de osaka (cot) para o tratamento de doenças inflamatórias
MX2018001075A (es) 2015-07-28 2019-04-15 Vyome Therapeutics Ltd Agentes terapeuticos y profilacticos antibacterianos.
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
KR20180050679A (ko) 2015-08-27 2018-05-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 통증 치료용 조성물 및 방법
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
US10457627B2 (en) 2015-09-23 2019-10-29 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
WO2017058828A1 (en) 2015-09-28 2017-04-06 Children's Hospital Los Angeles Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
AU2016329201A1 (en) 2015-09-30 2018-04-26 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
UA126549C2 (uk) 2015-10-01 2022-11-02 Хіт Байолоджикс, Інк. Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
US9808452B2 (en) 2015-10-01 2017-11-07 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2017064657A1 (en) 2015-10-16 2017-04-20 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
HUE065406T2 (hu) 2015-10-30 2024-05-28 Neurocrine Biosciences Inc Valbenazin-dihidroklorid sók és polimorfjaik
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
EP3373916A1 (en) 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
MX2018007421A (es) 2015-12-17 2018-08-15 Gilead Sciences Inc Compuestos inhibidores de quinasa de union a tank.
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2017117478A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
MX367669B (es) 2016-01-08 2019-08-30 Celgene Corp Compuestos antiproliferativos y sus composiciones farmacéuticas y usos.
TWI733734B (zh) 2016-01-08 2021-07-21 美商西建公司 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式，及其醫藥組合物及用途
US10648983B2 (en) 2016-01-08 2020-05-12 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
DK3402480T3 (da) 2016-01-11 2021-06-28 Epicentrx Inc Sammensætninger og fremgangsmåder til intravenøs administration af 2-brom-1-(3,3-dinitroazetidin-1-yl)ethanon
EP3411407B1 (en) 2016-02-05 2024-04-03 Orionis Biosciences BV Bispecific signaling agents and uses thereof
EP3848373A1 (en) 2016-02-19 2021-07-14 Phoenix Molecular Designs N-(1-((heterocyclyl)methyl)-1h-pyrazol-4-yl)-6-oxo-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[l,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2017152062A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CA3020681A1 (en) 2016-04-11 2017-10-19 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
EP3448851B8 (en) 2016-04-29 2022-04-27 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
EP3452473A1 (en) 2016-05-04 2019-03-13 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
MX2018013985A (es) 2016-05-20 2019-08-22 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y sus usos como agentes terapéuticos.
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CA3029457A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
RU2744615C2 (ru) 2016-07-18 2021-03-11 Фармена С.А. Использование 1-метилникотинамида для лечения заболеваний, связанных с c-реактивным белком
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
WO2018023072A2 (en) 2016-07-29 2018-02-01 Sunovion Pharmaceuticals, Inc. Compounds and compositions and uses thereof
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CA3036195A1 (en) 2016-09-07 2018-03-15 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
WO2018053190A1 (en) 2016-09-14 2018-03-22 Gilead Sciences, Inc. Syk inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
KR20190058550A (ko) 2016-09-19 2019-05-29 메이 파마, 아이엔씨. 병용 요법
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018069312A1 (en) 2016-10-11 2018-04-19 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
SG11201903312VA (en) 2016-10-14 2019-05-30 Epicentrix Inc Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
EP3528805B1 (en) 2016-10-21 2023-12-06 Cedars-Sinai Medical Center Simvastatin and chemotherapeutic conjugates comprising a heptamethine carbocyanine dye for resensitising human tumors to hormonal antagonists and chemotherapy
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
DK3534885T3 (da) 2016-11-03 2021-04-12 Kura Oncology Inc Farnesyltransferase-inhibitorer til anvendelse i behandling af kræft
TW201828932A (zh) 2016-11-09 2018-08-16 美商諾沃麥迪斯有限責任公司 1,1-二甲基雙胍之亞硝酸鹽、醫藥組合物及使用方法
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
BR112019010880A2 (pt) 2016-11-28 2019-10-01 Praxis Prec Medicines Inc compostos e seus métodos de uso
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
WO2018102673A1 (en) 2016-12-02 2018-06-07 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
MA48583A (fr) 2016-12-09 2021-04-21 Xenon Pharmaceuticals Inc Composés de benzènesulfonamide et leur utilisation en tant qu'agents thérapeutiques
WO2018115888A1 (en) 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant
US10784877B2 (en) 2016-12-21 2020-09-22 Johnson & Johnson Vision Care, Inc. Extended period timer circuits for ophthalmic devices
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3565834A1 (en) 2017-01-04 2019-11-13 The Research Institute at Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
KR20230038601A (ko) 2017-01-27 2023-03-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 ｖｍａｔ2 억제제의 투여 방법
JP7062010B2 (ja) 2017-01-27 2022-05-02 セルジーン コーポレイション ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ
EP3576765A4 (en) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. TARGETED ENGINEERING INTERFERON AND USES OF IT
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
JP7476467B2 (ja) 2017-02-06 2024-05-01 オリオンズ バイオサイエンス ビーブイ 標的化キメラタンパク質及びその使用
CA3049690C (en) 2017-02-06 2023-03-21 Spero Therapeutics, Inc. Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
EP3582815A1 (en) 2017-02-16 2019-12-25 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
EP3432883B1 (en) 2017-02-21 2021-07-28 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US11192933B2 (en) 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
CN110799192A (zh) 2017-03-27 2020-02-14 加利福尼亚大学董事会 治疗癌症的组合物和方法
EP3601291A1 (en) 2017-03-29 2020-02-05 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CN111093658B (zh) 2017-05-19 2022-10-14 恩福莱克逊治疗有限公司 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
US11161845B2 (en) 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
US20200155526A1 (en) 2017-05-31 2020-05-21 The Children's Medical Center Corporation Targeting lysine demethylases (kdms) as a therapeutic strategy for diffuse large b-cell lymphoma
JP2020522504A (ja) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ 多環式化合物およびそれらの用途
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019005874A1 (en) 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MY200746A (en) 2017-08-07 2024-01-13 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
JP6934562B2 (ja) 2017-08-22 2021-09-15 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
EP3691658A4 (en) 2017-10-04 2021-06-23 The Regents of The University of California IMMUNOMODULATOR OLIGOSACCHARIDES
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20200340060A1 (en) 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
EP3713916A1 (en) 2017-11-20 2020-09-30 Kiakos, Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3088630A1 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
WO2019126136A2 (en) 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
WO2019133901A1 (en) 2017-12-28 2019-07-04 Reviva Pharmaceuticals, Inc. Methods for treating pulmonary fibrosis
US11510901B2 (en) 2018-01-08 2022-11-29 Epicentrx, Inc. Methods and compositions utilizing RRx-001 combination therapy for radioprotection
TWI823890B (zh) 2018-01-10 2023-12-01 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
AU2019212435B2 (en) 2018-01-24 2022-03-10 Purdue Pharma L. P. Sleep disorder treatment and prevention
AU2019215440A1 (en) 2018-02-05 2020-08-27 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3752532A1 (en) 2018-02-12 2020-12-23 Diabetes-Free, Inc. Improved antagonistic anti-human cd40 monoclonal antibodies
AU2019221568B2 (en) 2018-02-15 2021-04-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating HIV infection
WO2019161307A1 (en) 2018-02-16 2019-08-22 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
US20210008030A1 (en) 2018-02-16 2021-01-14 Sunovion Pharmaceuticals Inc. Methods of treating social function disorders
PL3752496T3 (pl) 2018-02-16 2023-11-27 Gilead Sciences, Inc. Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
JP7354123B2 (ja) 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法
US11759417B2 (en) 2018-02-28 2023-09-19 Shanghai Wd Pharmaceutical Co., Ltd Pharmaceutical composition and preparation method therefor and use thereof
MX2020008972A (es) 2018-03-02 2020-10-05 Univ Oregon Health & Science Profármacos de amidas de moduladores de receptores nucleares de moléculas pequeñas.
JP7384815B2 (ja) 2018-03-22 2023-11-21 ザ チルドレンズ メディカル センター コーポレーション 肺の修復に関する方法および組成物
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
CN112118886B (zh) 2018-05-23 2022-08-23 上海汉都医药科技有限公司 活性药物成分的控释系统及其制备方法
EP3801535A4 (en) 2018-05-30 2022-03-02 Praxis Precision Medicines, Inc. ION CHANNEL MODULATORS
CN112262142B (zh) 2018-06-13 2023-11-14 泽农医药公司 苯磺酰胺化合物及其作为治疗剂的用途
KR20210021006A (ko) 2018-06-14 2021-02-24 뉴로크린 바이오사이언시즈 인코퍼레이티드 Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
AU2019297362B2 (en) 2018-07-06 2022-05-26 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
JP7199502B2 (ja) 2018-07-06 2023-01-05 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
KR20210030973A (ko) 2018-07-11 2021-03-18 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
AU2019307500B2 (en) 2018-07-16 2022-09-29 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
PE20211065A1 (es) 2018-07-27 2021-06-09 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物
US11945813B2 (en) 2018-08-07 2024-04-02 Firmenich Incorporated 5-substituted 4-amino-1H-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
CN112912141A (zh) 2018-08-27 2021-06-04 斯皮诺吉尼克斯公司 用于树突棘生成的肌成束蛋白结合化合物
US12030858B2 (en) 2018-08-27 2024-07-09 Oregon Health & Science University PARP inhibitors for treating cancer and asthma
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3109354A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
EP3844158A1 (en) 2018-08-31 2021-07-07 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
JP7450606B2 (ja) 2018-08-31 2024-03-15 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヘテロアリール置換スルホンアミド化合物および治療剤としてのそれらの使用
CA3111795A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CA3117968A1 (en) 2018-11-01 2020-05-07 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
RS62970B1 (sr) 2018-11-19 2022-03-31 Global Blood Therapeutics Inc 2-formil-3-hidroksifeniloksimetil jedinjenja sposobna da moduliraju hemoglobin
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
JP7406264B2 (ja) 2018-11-20 2023-12-27 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのシアノアリール－アニリン化合物
JP2022511127A (ja) 2018-11-20 2022-01-28 エヌフレクション セラピューティクス インコーポレイテッド あざの処置のためのアリールアニリンおよびヘテロアリールアニリン化合物
EP4233865A3 (en) 2018-11-20 2023-09-27 NFlection Therapeutics, Inc. Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
JP2022513159A (ja) 2018-11-29 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Ｒｎａを調節する方法
JP2022513449A (ja) 2018-12-12 2022-02-08 オートバーン セラピューティクス，インク． 新規な甲状腺模倣物
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
CA3124616A1 (en) 2018-12-21 2020-06-25 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US20220133894A1 (en) 2019-02-06 2022-05-05 Oregon Health & Science University Bisphosphonate-linked compounds
WO2020163554A1 (en) 2019-02-06 2020-08-13 Dice Alpha, Inc. Il-17a modulators and uses thereof
CN113677681A (zh) 2019-02-11 2021-11-19 凤凰分子设计公司 Rsk抑制剂的结晶形式
CA3130848A1 (en) 2019-02-22 2020-08-27 Kronos Bio, Inc. Solid forms of condensed pyrazines as syk inhibitors
JP2022521431A (ja) 2019-02-25 2022-04-07 シーエイチディーアイ ファウンデーション，インコーポレーテッド 変異型ハンチンチンタンパク質を標的とするための化合物及びその使用
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
KR20220004959A (ko) 2019-02-27 2022-01-12 액팀 테라퓨틱스, 인코퍼레이티드 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
US11597703B2 (en) 2019-03-07 2023-03-07 Histogen, Inc. Caspase inhibitors and methods of use thereof
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
WO2020190604A1 (en) 2019-03-15 2020-09-24 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3941900A1 (en) 2019-03-22 2022-01-26 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
CN113795253A (zh) 2019-03-29 2021-12-14 库拉肿瘤学公司 用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
JP2022527825A (ja) 2019-04-03 2022-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
KR20220016086A (ko) 2019-05-03 2022-02-08 프락시스 프리시젼 메디신즈, 인크. Kcnt1 억제제 및 사용 방법
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
CN113874375A (zh) 2019-06-03 2021-12-31 株式会社大分大学先端医学研究所 用于治疗狂犬病的环状酰胺化合物及其方法
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
EP3986163A2 (en) 2019-06-19 2022-04-27 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
US20220275064A1 (en) 2019-07-08 2022-09-01 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
JP2022540253A (ja) 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
EP3997068A1 (en) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
EP4003314B1 (en) 2019-07-26 2024-07-10 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
EP4021479A2 (en) 2019-08-27 2022-07-06 Tonix Pharma Limited Modified tff2 polypeptides
KR20220101075A (ko) 2019-09-16 2022-07-19 다이스 알파, 인크. Il-17a 조절인자 및 이의 용도
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
US20230008367A1 (en) 2019-09-26 2023-01-12 Abionyx Pharma Sa Compounds useful for treating liver diseases
TW202126631A (zh) 2019-10-01 2021-07-16 美商分子皮膚療法公司 作為klk5/7雙重抑制劑之苯并酮化合物
TW202128627A (zh) 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CN114929676A (zh) 2019-11-01 2022-08-19 紫丁香疗法有限公司 作为乙醇酸氧化酶抑制剂的杂环羧酸酯化合物
KR20220113943A (ko) 2019-11-12 2022-08-17 액팀 테라퓨틱스, 인코퍼레이티드 면역자극성 박테리아 전달 플랫폼 및 치료 제품의 전달을 위한 이의 용도
KR20220101099A (ko) 2019-11-13 2022-07-19 랩트 테라퓨틱스, 인크. C-c 케모카인 수용체 유형 4 길항제의 결정 형태 및 이의 용도
AU2020388387A1 (en) 2019-11-22 2022-06-02 President And Fellows Of Harvard College Ionic liquids for drug delivery
AU2020391466B2 (en) 2019-11-26 2024-05-23 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
KR20220121238A (ko) 2019-11-27 2022-08-31 프락시스 프리시젼 메디신즈, 인크. 이온 채널 조절제의 제형 및 이온 채널 조절제의 제조 및 사용 방법
KR20220110243A (ko) 2019-12-02 2022-08-05 셀진 코포레이션 암의 치료를 위한 요법
JP7453399B2 (ja) 2020-02-24 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ感染症を治療するための四環式化合物及びその使用
CA3171473A1 (en) 2020-02-24 2021-09-02 Exelixis, Inc. Compounds and methods of use
US20230093147A1 (en) 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
CA3176429A1 (en) 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
WO2021202796A1 (en) 2020-04-01 2021-10-07 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
KR20220160645A (ko) 2020-04-02 2022-12-06 길리애드 사이언시즈, 인코포레이티드 Cot 저해제 화합물의 제조 방법
CA3180661A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
WO2021222359A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
CA3181583A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
CN115996751A (zh) 2020-04-28 2023-04-21 哈佛大学校长及研究员协会 与离子液体佐剂有关的方法和组合物
WO2021226033A1 (en) 2020-05-07 2021-11-11 President And Fellows Of Harvard College Hyaluronic acid drug conjugates
US20230173095A1 (en) 2020-05-29 2023-06-08 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
PL4153136T3 (pl) 2020-06-10 2024-06-24 Auspex Pharmaceuticals, Inc. Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US20230102840A1 (en) 2020-06-23 2023-03-30 President And Fellows Of Harvard College Compositions and methods relating to combinatorial hyaluronic acid conjugates
AU2021296607B2 (en) 2020-06-25 2024-07-25 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
WO2022006228A1 (en) 2020-06-30 2022-01-06 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
WO2022008976A1 (en) 2020-07-10 2022-01-13 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
EP4188542A1 (en) 2020-08-03 2023-06-07 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
EP4196139A2 (en) 2020-08-12 2023-06-21 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
AU2021326546A1 (en) 2020-08-14 2023-04-13 Siteone Therapeutics, Inc. Non-hydrated ketone inhibitors of NaV1.7 for the treatment of pain
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
TW202222798A (zh) 2020-09-30 2022-06-16 美商基利科學股份有限公司 橋接三環胺甲醯基吡啶酮化合物及其用途
WO2022069701A1 (en) 2020-10-01 2022-04-07 Nogra Pharma Limited Methods of treating pulmonary fibrosis
US20220133669A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
EP4267559A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. Substituted indole compounds
TW202241419A (zh) 2020-12-22 2022-11-01 美商基利科學股份有限公司 ６－取代之吲哚化合物
WO2022155410A1 (en) 2021-01-15 2022-07-21 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
KR20230134529A (ko) 2021-01-19 2023-09-21 길리애드 사이언시즈, 인코포레이티드 치환된 피리도트리아진 화합물 및 이의 용도
US20240115607A1 (en) 2021-01-26 2024-04-11 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
WO2022164997A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
TW202245758A (zh) 2021-02-08 2022-12-01 美商全球血液治療公司 作為丙酮酸激酶活化劑之吡咯啶-吡唑
JP2024505721A (ja) 2021-02-09 2024-02-07 ギリアード サイエンシーズ， インコーポレイテッド チエノピロール化合物
WO2022178205A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
WO2022187573A1 (en) 2021-03-05 2022-09-09 President And Fellows Of Harvard College Methods and compositions relating to cell membrane hybridization and camouflaging
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CR20230472A (es) 2021-03-10 2024-03-21 Dice Molecules Sv Inc Inhibidores de integrina alpha v beta 6 y alpha v beta 1 y sus usos
WO2022198002A1 (en) 2021-03-19 2022-09-22 Tiba Biotech Llc Artificial alphavirus-derived rna replicon expression systems
TW202302598A (zh) 2021-04-16 2023-01-16 美商基利科學股份有限公司 噻吩并吡咯化合物
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4337659A1 (en) 2021-05-14 2024-03-20 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
WO2022265880A1 (en) 2021-06-16 2022-12-22 President And Fellows Of Harvard College Improved methods and compositions for drug delivery relating to ionic liquids
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
WO2023278843A2 (en) 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant
CN117980309A (zh) 2021-08-05 2024-05-03 百时美施贵宝公司 用作her2抑制剂的三环稠合嘧啶化合物
EP4396380A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
WO2023034506A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin
EP4396331A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
EP4396578A1 (en) 2021-09-01 2024-07-10 Flagship Pioneering Innovations VI, LLC Methods and compositions for promoting adipocyte beiging
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023039162A1 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating enteroendocrine cells
WO2023039164A2 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating goblet cells and for muco-obstructive diseases
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
WO2023043827A2 (en) 2021-09-14 2023-03-23 Flagship Pioneering Innovations Vi, Llc Methods and compositions for perturbing monocyte and neutrophil lineages
TW202328120A (zh) 2021-09-24 2023-07-16 加拿大商再諾製藥公司 做為鈉通道活化劑之吡啶衍生物及其用途
CA3231743A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinylacetamide derivatives as sodium channel activators
CN118251389A (zh) 2021-09-24 2024-06-25 泽农医药公司 作为钠通道活化剂的吡啶基衍生物
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
WO2023060134A1 (en) 2021-10-06 2023-04-13 Global Blood Therapeutics, Inc. Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
WO2023059846A1 (en) 2021-10-08 2023-04-13 President And Fellows Of Harvard College Ionic liquids for drug delivery
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
WO2023069770A1 (en) 2021-10-22 2023-04-27 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2023097233A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097234A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097230A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023102378A1 (en) 2021-11-30 2023-06-08 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
CN118355020A (zh) 2021-12-03 2024-07-16 吉利德科学公司 Hiv病毒感染的治疗性化合物
US20230212148A1 (en) 2021-12-03 2023-07-06 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
IL312718A (en) 2021-12-03 2024-07-01 Gilead Sciences Inc Therapeutic compounds for HIV infection
TW202339732A (zh) 2021-12-10 2023-10-16 美商全球血液治療公司 投予血紅素調節劑的方法
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023137178A1 (en) 2022-01-17 2023-07-20 Chandrasekhar Satishchandran Combinations of vitamin d3, niacinamide and lipoic acid for use in the maintenance of healthy blood glucose levels
WO2023147135A1 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
WO2023147134A2 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
TW202400593A (zh) 2022-03-28 2024-01-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ家族離胺酸乙醯轉移酶之抑制劑
WO2023192904A1 (en) 2022-03-30 2023-10-05 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2023192506A1 (en) 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023201282A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
WO2023215220A1 (en) 2022-05-02 2023-11-09 Esperion Therapeutics, Inc. Macrocyclic inhibitors of atp citrate lyase
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2023225162A1 (en) 2022-05-20 2023-11-23 Gilead Sciences, Inc. Antiviral indolinyl compounds and uses thereof
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US20240101531A1 (en) 2022-06-08 2024-03-28 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators
TW202408485A (zh) 2022-06-13 2024-03-01 美商埃皮辛特瑞科斯公司 用於減少癌症治療中不良副作用之組合物及方法
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2023244584A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024015827A1 (en) 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Solid forms of a triazine derivative as cbl-b modulator
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2024015416A1 (en) 2022-07-15 2024-01-18 Celloram Inc. Celastrol derivatives
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
WO2024091863A1 (en) 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024092043A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridine compounds
US20240174672A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridone Compounds
WO2024089668A1 (en) 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof
US20240165112A1 (en) 2022-11-04 2024-05-23 Bristol-Myers Squibb Company Therapy for the treatment of cancer
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy
US11931224B1 (en) * 2022-12-19 2024-03-19 Robert Parker Tooth pod
WO2024145662A1 (en) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023499A (en) * 1910-09-20 1912-04-16 Ralcy Husted Bell Collapsible capsule.
US1279564A (en) * 1918-02-28 1918-09-24 Frederick Stearns & Company Method of forming medicine-injectors.
US1434531A (en) * 1919-01-29 1922-11-07 Lloyd W Cyrenius Ampullar container for liquids or semisolids
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US2962023A (en) * 1955-10-28 1960-11-29 Chappaz Gaston Medicator
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3574820A (en) * 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0100424A2 (en) * 1982-06-30 1984-02-15 Merck & Co. Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
EP0100424A3 (en) * 1982-06-30 1984-11-21 Merck & Co. Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance

Also Published As

Publication number Publication date
IL42418A0 (en) 1973-07-30
IE39952B1 (en) 1979-02-14
NL163721C (nl) 1980-10-15
JPS4961325A (hr) 1974-06-14
BR7304196D0 (pt) 1974-07-25
IL42418A (en) 1975-07-28
GB1415210A (en) 1975-11-26
ZA733734B (en) 1974-06-26
IE39952L (en) 1973-12-05
AR199301A1 (es) 1974-08-23
JPS596843B2 (ja) 1984-02-15
NL163721B (nl) 1980-05-16
ES415568A1 (es) 1976-05-16
US3845770A (en) 1974-11-05
NL7307699A (hr) 1973-12-07
FR2188568A5 (hr) 1974-01-18

Similar Documents

Publication Publication Date Title
JPS4961325A (hr)
JPS4977939A (hr)
CS152750B1 (hr)
CS158503B1 (hr)
CS161020B1 (hr)
CS159552B1 (hr)
CS161325B1 (hr)
CS156378B1 (hr)
CS155400B1 (hr)
CS154079B1 (hr)
CS153317B1 (hr)
CS153299B1 (hr)
CS161337B1 (hr)
CH580921A5 (hr)
CH590264A5 (hr)
CH570644B5 (hr)
CH571311A5 (hr)
CH571551A5 (hr)
CH573048A5 (hr)
CH575057A5 (hr)
CH577604A5 (hr)
CH578472A5 (hr)
CH580193B5 (hr)
CH580625A5 (hr)
CH595428A5 (hr)

Legal Events

Date Code Title Description
PL Patent ceased